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Mammalian hosts have evolved protein “restriction factors” to combat retroviruses. 
TRIM5α and the related TRIMCyp protein (collectively TRIM5), are restriction factors 
that can potently restrict retroviruses, including HIV-1, by binding their capsids and 
blocking reverse transcription. Previous studies have shown that the C-terminal 
SPRY/CypA domains of TRIM5 proteins bind the capsids of susceptible retroviruses and 
that higher-order oligomerization of TRIM5 proteins apparently also contributes to capsid 
binding. However, the biochemical and structural details of these interactions are not fully 
understood. To study how TRIM5 proteins recognize capsids, we have developed new 
methods for expressing and purifying recombinant TRIM5 proteins. Here, we report 
biochemical, electron microscopic and X-ray crystallographic studies of pure recombinant 
TRIM5 proteins and their complexes with authentic HIV-1 core particles and in vitro-
assembled mimics of the HIV-1 capsid surface. 
In Chapter 2, we report the expression, purification and electron crystallographic 
studies of a restrictive, but non-native chimeric rhesus TRIM5 protein (TRIM5-21R), and 
show that TRIM5-21R can spontaneously self-assemble into paracrystalline hexagonal 
lattices comprising 6-sided rings. Moreover, ring assembly is promoted by TRIM5-21R 
binding to hexagonal HIV-1 CA assemblies. In Chapter 3, we report the first crystal 
structure of a TRIM coiled-coil domain (from human TRIM25) as well as supporting 
analytical ultracentrifugation and disulfide crosslinking experiments showing that other 
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TRIM coiled-coils, including TRIM5, also form antiparallel dimers that are ~170 Å long. 
In Chapter 4, we describe the expression and purification of 11 different mammalian 
TRIM5 alleles. We demonstrate that TRIM5 hexagonal assembly is a conserved property 
and report electron microscopic and biochemical studies showing that TRIM5 proteins 
form a ~35 nm-spaced, flexible hexagonal “net” on the surface of decorated HIV-1 cores 
and other capsid mimics. In Chapter 5, I present my ongoing attempts to crystallize and 
determine the structure of the TRIM5α core domains in the assembled state. 
Taken together, my work supports a “pattern recognition” model for capsid recognition 
in which TRIM5 proteins have evolved to restrict a variety of different retroviruses by 
cooperatively assembling flexible hexagonal nets that can bind avidly and adapt to the 
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The human immunodeficiency virus / acquired immune deficiency syndrome 
(HIV/AIDS) pandemic infects an estimated 35.3 million people, with 2.3 million new 
infections each year (1). Although highly active antiretroviral therapy (HAART) has 
contributed to a measurable decline in the number of AIDS deaths, from 2.3 million in 
2005 to 1.6 million in 2012, significant challenges nonetheless prevent disease eradication. 
The high cost and limited availability of HAART in the developing world, the rapid 
emergence of drug resistance and HIV’s ability to escape sterilizing immunity by 
establishing latent reservoirs in patients necessitate continued HIV research (2).  
An exciting new direction that has gained prominence in retrovirology, and 
microbiology in general, is the discovery and characterization of mammalian intrinsic 
immune pathways that counteract viral replication (3). Antiviral molecules that mediate 
such pathways are collectively termed “restriction factors” and their study could, in 
principle, lead to new therapeutic strategies against HIV type 1 (HIV-1) (4-6). Here, I 





1.1 Structure of HIV-1 and its mature capsid 
HIV-1 is an enveloped virus of the Lentivirus genus in the Retroviridae family. Its 
positive-sense single-stranded RNA genome encodes 3 major polyproteins: Gag, Gag-Pol 
and Env; and 6 accessory or regulatory proteins: Tat, Rev, Nef, Vpr, Vif and Vpu (7). 
Together, these viral proteins organize the virion and orchestrate the different steps of viral 
replication. HIV-1 virions exist in two forms – a noninfectious immature form that is 
initially released from producer cells and a mature form that is generated by subsequent 
proteolytic processing of Gag and Gag-Pol and rearrangement of the processed proteins 
(reviewed in (8)). Autoproteolysis by the PR domain of Pol releases the Pol-derived viral 
enzymes, reverse transcriptase (RT), integrase (IN) and protease (PR), and the Gag-derived 
structural proteins, MA, CA, NC, as well as three smaller spacer peptides, SP1, SP2 and 
p6. The Golgi-resident host enzyme furin cleaves Env into gp120 (SU) and gp41 (TM). 
The uncleaved Gag polyprotein organizes the immature virion and also coordinates viral 
assembly and egress from producer cells (9). The processed MA, CA and NC proteins then 
dramatically reorganize to form the mature virion. 
Figure 1.1A shows an electron micrograph (left) and a more detailed schematic (right) 
of a mature HIV-1 virion. Immature virions vary in size, but are typically ~110-120 nm in 
diameter. The HIV-1 limiting membrane is derived from the host lipid bilayer and is rich 
in cholesterol and acidic phospholipids (10). Approximately 7-14 trimeric Env “spikes” 
(comprising gp120 and gp41) decorate the outer surface of the viral membrane (11) and 
myristoylated MA trimers form a “matrix” layer against the inner bilayer (12-14). The 
central electron-dense, conical ribonucleoprotein assembly is known as the viral core. The 












Figure 1.1 Structure of the mature HIV-1 virion. (A) Electron micrograph of a mature HIV-
1 virion (left) and a cartoon schematic of its major components (right). 
(B) Structure of the mature HIV-1 capsid. Cartoon representation of a HIV-1 CA monomer 
showing the N-terminal (NTD, orange) and C-terminal (CTD, blue) domains (left), surface 
representation of a CA hexamer surrounded by 6 neighboring CA hexamers in cartoon 
representations (middle) and a model of a HIV-1 fullerene cone (right), with insets 











“nucleocapsid”) as well as the viral proteins IN, RT and Vpr, within an outer CA protein 
shell (called the “capsid”). 
Structural studies have led to an atomic-level understanding of the mature HIV-1 capsid 
structure (15-27). CA monomers comprise α-helical N-terminal (NTD; orange) and C-
terminal (CTD; blue) domains, which are connected by a flexible linker (Figure 1.1B, left). 
The exact process by which ~1500 CA copies nucleate and grow into a mature capsid is 
not fully understood, but the structural contributions of the CA protein domains are clear 
(9). The NTD mediates CA hexamerization and the six outward-facing CTDs contact the 
CTDs of neighboring hexamers to form a hexagonal lattice, which is further stabilized by 
NTD-CTD interactions (Figure 1.1B, middle) (22). Lattice curvature is accommodated by 
changes in the “bite” angle between the NTD and CTD of individual CA monomers. The 
constituent CA subunits of the capsid are never identical to one another, because the capsid 
lacks global symmetry and curvature abolishes the perfect six-fold symmetry observed in 
crystal structures of the CA hexamer (21, 22, 27). The surface lattice therefore exhibits 
only local or “pseudo” six-fold symmetry about the axis of each hexamer (Figure 1.1B, 
right). Euler’s polyhedron theorem dictates that convex polyhedra assembled from 
hexameric building blocks can enclose space only if they also include (exactly) 12 
pentamers. Gratifyingly, CA also forms quasi-equivalent pentamers (Figure 1.1B, right, 
top inset) (23, 26), and their inclusion produces a conical capsid that is a “fullerene cone” 
(17, 23). 
The CA hexamer/pentamer model also accounts for the spherical and cylindrical 
capsids formed by other retroviral genera (17). Despite sharing <10% sequence identity, 




pentamers (20, 27, 28). Global variations in capsid morphology can, therefore, arise simply 
from differences in hexamer numbers and pentamer positions (29, 30). For example, the 
narrow and broad ends of the lentiviral fullerene cone shown in Figure 1.1B (right) have 5 
and 7 pentamers, respectively (a “P = 5,7” cone (17)), whereas pseudosymmetric 
distributions of 6 pentamers on either end would yield cylindrical capsids (which 
predominate in D-type retroviruses). Near-uniform pentamer distributions create roughly 
spherical capsids (present in C-type retroviruses), and finally, perfectly symmetrical 
distribution of the pentamers generates an icosahedral capsid. Although the majority of 
HIV-1 capsids belong to the P = 5,7 class, ~50% of HIV-1 core particles display wider 
cone angles, irregular or cylindrical shapes, and in those cases the capsids contain atypical 
pentamer distributions (Chapter 4 and refs. (17, 31-33)). Unlike regular, crystallizable 
capsids of icosahedral viruses, individual retroviral capsids differ from one another even 
within a morphological class (such as HIV-1 P = 5,7 cones) (34, 35). Thus, although 
retroviral capsids are highly organized, they are nevertheless asymmetric and highly 
pleomorphic. These properties have important implications for capsid recognition by host 
restriction factors such as TRIM5α (Section 1.6, Chapter 2, (36)). 
 
1.2 Overview of the HIV-1 lifecycle 
HIV-1 initially binds at the plasma membrane of target cells via interactions between 
the gp120 subunit of the viral Env glycoprotein and cell surface CD4 receptors. Receptor 
binding exposes additional binding sites for either of two chemokine co-receptors, CCR5 
or CXCR4. Coreceptor binding activates the transmembrane gp41 glycoprotein to fuse the 




There is some debate as to whether fusion occurs directly at the plasma membrane or from 
endosomes, following endocytosis (39, 40).  
Once the core is in the cytoplasm, three steps transform the core particle into a 
preintegration complex (PIC) (Figure 1.2A): (a) A “reverse transcription initiation 
complex” comprising RT, a tRNALys,3 primer and the two RNA copies (inset) initiates 
reverse transcription of the viral RNA into a complementary double-stranded DNA 
(cDNA), (b) the capsid “uncoats”, releasing CA subunits and (c) the PIC is actively 
transported across the cytoplasm and imported into the nucleus. The timing, order and sites 
of these steps are still controversial (represented in Figure 1.2A as a gray cloud). 
Proper capsid uncoating appears to be critical for efficient reverse transcription (and 
vice versa), because CA mutations that reduce capsid stability typically inhibit cDNA 
synthesis in vivo and conversely, reverse transcriptase inhibitors and mutations can alter 
the kinetics of capsid uncoating (41, 42). Early models of early events postulated that 
reverse transcription and uncoating occur immediately after cytoplasmic entry and that the 
newly formed PIC containing viral cDNA, IN and other viral and host factors is transported 
across the cytoplasm and imported into the nucleus. Exciting new findings, however, 
suggest a more direct role for the mature capsid lattice in nuclear targeting and import:  
(a) CA sequences dictate the ability of lentiviruses, including HIV-1, to infect non-
dividing cells that contain intact nuclear envelopes (43). (b) CA hijacks a nuclear transport 
factor, transportin 3 (TNPO3), by binding to its cellular substrate, cleavage and 
polyadenylation specificity factor subunit 6 (CPSF6), via a pocket located at the NTD-
CTD hexameric lattice interface. This observation implies that CA hexamers must be intact 








Figure 1.2 HIV-1 lifecycle. 
(A) Early events in the HIV-1 lifecycle. Entry: The viral membrane fuses with the plasma 
or endosomal membrane and the core particle enters the cytoplasm. Reverse Transcription: 
RT initiates and completes reverse transcription of the viral RNA. Uncoating: The capsid 
disassembles into low molecular weight forms of CA. Nuclear Import: The preintegration 
complex (PIC) is delivered into the nucleus. Integration: IN mediates integration of the 
viral cDNA into the host chromosome. Maroon dashed ellipses highlight the early-stage 
restriction factors Fv1, TRIM5α, TRIMCyp, SAMHD1, APOBEC3G, MxB. 
(B) Late events in the HIV-1 lifecycle. Transcription, Splicing, Nuclear Export: HIV-1 
proviral DNA is transcribed, spliced (in some cases) and exported out of the nucleus. 
Assembly: HIV-1 proteins are translated in the cytoplasm and on the ER (Env), and 
transported to the plasma membrane, where they assemble into nascent particles. Budding: 
The ESCRT machinery aids HIV-1 budding. Maturation: The released virus is processed 
by PR. Maroon dashed ellipses highlight the late stage restriction factors TRIM28, 















complex (NPC) components, NUP153 (using the same NTD-CTD pocket) and NUP358, a 
cyclophilin domain-containing protein (using the cyclophilin binding loop on the CA 
NTD). These observations imply that CA hexamers are also associated with PICs at this 
stage (45, 46). Finally, (d) mutations in CA (N74D, P90A) or competitive inhibitors (e.g., 
PF-74, BI-1, BI-2, cyclosporine) that disrupt these interactions affect uncoating and nuclear 
import, and also render the viral genome susceptible to restriction, suggesting that these 
host factors help uncoat the capsid just prior to PIC nuclear entry, thus shielding viral 
reverse transcripts from host restriction (44, 47-51). Collectively, these observations 
suggest that the intact capsid may deliver the PIC to the nuclear pore, or perhaps even 
through it (52). 
Once the PIC enters the nucleus, the dsDNA viral genome must be integrated into the 
host chromosomes. The process of integration is becoming better understood, owing 
especially to recent atomic resolution crystal structures that capture different steps in this 
process (53, 54). Integration is mediated by the intasome, a complex of tetrameric IN 
subunits that bind to the viral cDNA ends. Assisted by host factors such as lens epithelium-
derived growth factor, LEDGF, IN associates preferentially with highly-transcribed, non-
chromatin regions of the host chromosome, engages both strands of the target DNA in a 
ternary “target capture complex” and catalyzes concerted strand transfer of the viral cDNA 
ends in the chromosomal DNA (reviewed in (55, 56)). Host DNA repair machinery 
subsequently repairs the insertion wound (57). In summary, the early steps of entry, reverse 
transcription, uncoating, nuclear import and integration collectively create a DNA copy of 




HIV-1 proviruses can lie dormant in small populations of resting CD4+ memory T cells 
and in other infected cells within patient tissues, where they remain unaffected by HAART 
therapy (58, 59). These latently infected CD4+ memory T cells turn over with a half-life of 
years, but can be reactivated at any time, providing an enormous challenge for viral 
eradication. Except for these so-called “latent reservoirs”, the majority of infected cells 
transcribe their integrated DNA proviruses into mRNA, which launches the late events in 
HIV-1 replication. 
During the late stage steps in HIV-1 replication, RNA transcription is stimulated by the 
viral factor, Tat, which increases the processivity of host RNA Pol II complexes. Longer, 
unspliced RNAs are exported into the cytoplasm by the action of the viral Rev protein. 
Once in the cytoplasm, these RNAs can either serve as positive-strand genomes, or can 
code for regulatory proteins and structural proteins that assemble progeny virions (Figure 
1.2B). As copies of the genomic RNA and viral proteins accumulate, Gag orchestrates their 
trafficking, assembly and egress from the plasma membrane as nascent virions (reviewed 
in (8, 9)). The host endosomal sorting complexes required for transport (ESCRTs) facilitate 
HIV-1 budding and catalyze the final step of membrane fission, thus releasing immature 
virions and their newly acquired lipid membranes from the cell (60). Finally, PR cleaves 
the structural polyproteins, and the subunits then rearrange to produce mature infectious 
virions. 
 
1.3 Retroviral restriction factors 
In mammalian hosts, the innate immune system provides rapid, nonadaptive responses 




more specific response to viral (and other pathogenic) antigens. These two lines of defense, 
together with modern antiretroviral drugs, are the three most important defenses against 
the establishment and expansion of retroviral infections. It is desirable, however, to 
forestall retroviral infection and prevent viral spread to uninfected cells before proviruses 
(and latency) can be established. Unfortunately, prophylactic vaccines have so far only 
displayed modest (if any) success against HIV-1 (61, 62). Owing to the strong selective 
pressure of retroviral infections, mammals have evolved constitutively-expressed cellular 
genes, termed restriction factors, which can rapidly detect and block retroviral replication 
in cells (63). Restriction factors lack immunological memory to repeated infections, are 
highly specific towards particular pathogens and are typically induced by interferon 
signaling pathways that indicate the presence of foreign pathogens (3). Restriction factors 
function in concert with one other and with antiviral signaling pathways. Restriction factor 
expression is typically upregulated by interferon-α (IFN-α), IRF3, IRF7, AP-1 and NF-κB 
pathways, and conversely, can themselves trigger the release of IFN-α and other cytokines 
upon sensing retrovirus-associated patterns (such as viral RNA or capsids) (64-66). Such 
systemic responses to infection, although poorly understood, limit viral spread by 
coordinating multiple lines of defense and establishing an “antiviral state”. 
Existing clinical AIDS therapies target several different steps of the viral lifecycle. In 
fact, only combination therapies that target several different replication steps 
simultaneously can effectively lower HIV-1 titers in patients, owing to HIV-1’s astonishing 
ability to acquire drug resistance. Analogous selection pressures also dictate the evolution 
of antiretroviral restriction factors, which can again block nearly every step in the viral 




maroon dashed ellipses). The well-studied restriction factors that mediate early, postentry 
blocks to retroviral replication are: Fv1, TRIM5α and TRIMCyp, APOBEC3G, SAMHD1 
and Mx2, and the known restriction factors that block late events are: TRIM28, ZAP, 
Schlafen 11 and Tetherin (for reviews, see refs. (5, 63, 67)).  
Discoveries of restriction factors often resulted from observations that certain species 
(or cell types) support retroviral replication less well than others (Table 1.1). A related 
approach exploited the observations that normally permissive cells become non-permissive 
when infected with HIV-1 or SIV strains lacking accessory genes such as Vpu, Vif and 
Vpx (which antagonize Tetherin, APOBEC3G and SAMHD1, respectively). Diverse 
methods were used to identify the restricting protein, such as: comparative transcriptional 
profiling (as in the case of Tetherin and Mx2), biochemical and mass spectrometric 
analyses (SAMHD1, TRIM28), positional cloning (Fv1), reverse transcriptase PCR (RT-
PCR; TRIMCyp), cDNA subtraction assays (APOBEC3G) and cDNA library screens 
(TRIM5α) (for references, see Table 1.1). Future strategies will likely mimic current 
approaches, but may also include evolutionary and large-scale genomics techniques (68). 
A detailed summary of HIV-1 restriction factors is presented in Table 1.1. 
Restriction factors are specialized immune molecules that have typically evolved from 
proteins that serve other purposes but now function solely to combat HIV-1 (or other 
specific pathogens) and can therefore undergo extensive duplication, copy number 
variation and genetic drift to diversify their pathogen range and restriction mechanisms. 
This feature distinguishes them from host cell factors that aid HIV-1 replication, such as 
the ESCRT machinery, which are also under evolutionary pressure to escape usurpation, 
but cannot endlessly undergo positive selection without jeopardizing their cellular  
Table 1.1  
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Table 1.1 Retroviral restriction factors 
15 
 





functions (99). Members of the APOBEC family of restriction factors (AID, APOBEC1, 
APOBEC3A-G, etc.), for instance, mediate varied immune functions, including antibody 
gene diversification and restriction of nonretroviruses (e.g., hepatitis B virus) (100). 
Another important example is the tripartite motif-containing (TRIM) family of restriction 
factors, which has expanded dramatically in humans to contain related but distinct genes, 
including TRIM5 (Section 1.4). 
Many restriction factors are evolving rapidly across primates, as evidenced by a non-
synonymous to synonymous mutation ratio (dN/dS), >1 in their pathogen interaction 
domains, which indicates that the region is under positive selection (99, 101-106). Positive 
selection is a consequence of an arms race for survival, the so-called “Red Queen” effect, 
in which hosts evolve new restriction factors and retroviruses counter-evolve escape 
strategies ad infinitum (68, 107) (a reference to Lewis Carroll’s Red Queen’s observation 
that “It takes all the running one can do, just to stay in the same place”.) Both modern-day 
retroviruses and their hosts bear evolutionary imprints of this arms race. For example, the 
host factor APOBEC3G blocks retroviral replication by deaminating cytidine to uracil in 
nascent, minus-strand DNA during reverse transcription and as a consequence the genomes 
of extant lentiviruses are AU-rich (108). Similarly, simian immunodeficiency virus (SIV) 
Nef and Vpr can downregulate tetherin (from non-human primates), a cell surface 
restriction factor that tethers escaping virions (109, 110), but human tetherin has evolved 
to lack five residues that determine Nef susceptibility (103). Remarkably, this adaptation 
in humans drove the emergence of HIV-1 Vpu, which efficiently triggers the lysosomal 




At first glance, retroviruses may appear to have won the battle against host restriction 
systems for they continue to colonize mammals, as the AIDS pandemic attests. Restriction 
factors do, however, protect modern hosts against cross-species transmissions of infections 
(i.e., zoonotic spread) and limit retroviral species tropism (3). Indeed, paleovirological 
studies have uncovered several examples of ancient retroviruses that have evolved 
dramatically or have gone extinct owing to selection pressure from restriction factors (112-
114). 
There are indications that an understanding of HIV-1 restriction factors could result in 
novel AIDS therapies, even though none currently exist in the market (reviewed in (4, 115-
117)). High-throughput screening studies have identified small molecule lead compounds 
(RN-18, IMB-26, IMB-35, VEC-5, MM-1 and MM-2) that prevent Vif-induced 
proteasomal degradation of human APOBEC3G (118-121). Another promising strategy is 
to inhibit human APOBEC3G itself (122), because adaptive evolutionary diversity in HIV-
1 strains arises partly from APOBEC3G-induced viral hypermutation (123, 124). Possible 
therapeutic strategies for augmenting TRIM5α and TRIMCyp, the restriction factors that 
are the focus of this dissertation, are discussed in Section 1.7. 
 
1.4 The TRIM protein family 
The Tripartite Motif (TRIM) family of proteins is present in both invertebrates and 
vertebrates and comprises over 100 genes in humans (125-132). Some TRIMs (called 
group 1 TRIM genes (133)) perform varied, evolutionarily-ancient roles during cellular 




others (group 2) are species-specific, positively-selected genes that are upregulated during 
viral infection and are, therefore, bona fide antiviral restriction factors (65, 134). 
By definition, the tripartite motif comprises an ordered arrangement of a RING (really 
interesting new gene) domain, one or two B-box domains (B-box 1 and B-box 2) and a 
coiled-coil (abbreviated as RBCC), depicted schematically in Figure 1.3. Individual TRIM 
proteins can sometimes lack one or more of these domains, but even in those cases, the 
remaining domains strictly follow this order. TRIM proteins differ from one another in the 
varied domain(s) that follows the RBCC domains, and the family itself is more extensively 
classified into 11 subfamilies (C-I to C-XI) based on these C-terminal domains (135, 136). 
For more detailed representations of the RBCC and C-terminal domains of individual 
TRIMs, see refs. (66, 67, 136).  
TRIM restriction factors have so far been identified using diverse methods such as viral 
restriction screens, interferon induction profiling, functional genomics and evolutionary 
approaches, but the task is nevertheless difficult and each method suffers from specific 
shortcomings (65, 137-140). One difficulty arises from the fact that many TRIM genes 
undergo alternative splicing to produce as many as 11 different isoforms, not all of which 
possess restriction ability (137). Another challenge is that the species- and virus-specific 
nature of restriction implies that even broad-based functional approaches cannot uncover 
every antiviral TRIM (139, 141). Finally, although some TRIM restriction factors can be 
identified by dN/dS analyses, several other genes that are essential for restriction 
nevertheless do not display signs of positive selection (137). A case in point is murine 
TRIM28, which is essential for retroviral transcriptional silencing in the germline (Table 
































proviral DNA (via the bridging zinc finger protein ZFP809 (142)). For these reasons, many 
TRIM family members remain poorly characterized, although there are a few well-studied 
members. 
 
1.4.1 TRIM5α and TRIMCyp 
The search for suitable primate models for AIDS in the 1990s led to the interesting 
observation that many non-human primate cells resist HIV-1 infection (73, 143). The 
phenotype was labeled “lentivirus-susceptibility 1” (Lv1) and a similar N-MLV restriction 
activity in human cells was referred to as Ref1. In 2004, Stremlau, Sodroski and colleagues 
identified the alpha-isoform of TRIM5 as the restriction factor that blocks HIV-1 
replication in rhesus macaque cells (Table 1.1) (72). Subsequently, they and several other 
groups demonstrated that TRIM5α is responsible for the previously documented Lv1 and 
Ref1 activities (74, 75, 144). TRIM5α mediates an early, postentry block to retroviral 
replication prior to reverse transcription. The protein comprises RING, B-box 2 and coiled-
coil domains followed by a C-terminal PRYSPRY (B30.2) domain that binds directly to 
retroviral capsids (Figure 1.3) (145). Owing to its importance in retroviral restriction, 
TRIM5α has become one of the best-studied members of the TRIM protein family. 
A notable TRIM5 variant, TRIMCyp, has evolved independently in the Aotus (owl 
monkey) and Macaca (macaques) genera of new world and old world monkeys, 
respectively. TRIMCyp contains a capsid-binding cyclophilin A (CypA) domain in place 
of the PRYSPRY domain of TRIM5α (see Figure 1.4) (76-81). In most cell types, CypA is 
an essential co-factor for HIV-1 replication that participates in capsid uncoating and/or 












Figure 1.4 General steps in TRIM5 protein restriction of HIV-1. Capsid Recognition: 
Soluble cytoplasmic TRIM5 dimers must recognize mature retroviral capsids. 
Ubiquitylation: The RING domains dimerize and recruit the Ubc13/Uev1A heterodimeric 
E2 complex to catalyze the synthesis of K63-linked polyubiquitin chains. Signaling and 
Restriction: TAB2/TAB3 ubiquitin adapters recruit the TAK1 kinase complex and initiate 
NF-κB and AP-1 signaling. The proteasome somehow accelerates capsid disassembly and 
leads to a block in reverse transcription. In addition, TRIM5 can also target CA for 














thus conferred owl monkeys and macaques with a potent restriction factor from which the 
virus cannot easily evade by evolving CypA-binding escape mutations. 
 
1.5 Structures of TRIM protein domains 
TRIM proteins are constitutive coiled-coil domain-mediated oligomers (148). 
Although initial reports incorrectly characterized some TRIM proteins as trimeric (149, 
150), we and others have demonstrated that the elongated, ~17 nm long coiled-coil domain 
forms an antiparallel dimer (Figure 1.5). The chemically-crosslinked, elongated dimer 
migrates anomalously slowly by SDS-PAGE, however, explaining the initial trimeric 
assignment (see Appendix, Chapter 2, 3, (151, 152)). To date, only TRIM5 and TRIM25 
have been formally shown to be dimeric (151-154), but identical ‘knobs-into-holes’ 
patterns of hydrophobic coiled-coil residues are conserved among many family members, 
indicating that all TRIM proteins form dimers. Most TRIM proteins appear to 
homodimerize preferentially, although heterodimers of closely related TRIMs are also 
possible (148)). 
The coiled-coil also forms a “platform” that orients the TRIM binding domains (e.g., 
the PRYSPRY domain in the case of TRIM5α) and can recruit TRIM binding partners. In 
at least some cases, members of the melanoma antigen (MAGE) family of ~60 human 
proteins bind specifically to TRIM coiled-coil domains. The MAGE proteins appear to 
provide an ‘E4’ activity that somehow enhances TRIM E3 function (155). 
TRIM proteins constitute the largest family of human RING-containing proteins, and 
have been shown to act as E3 Ub ligases, and/or in several instances (156), as E3 SUMO 






Figure 1.5 Representative 3-dimensional structures of TRIM domains. RING (yellow): 
Overlay of RING domain structures from human TRIM5α (2ECV), TRIM34 (2EGP), 
TRIM30 (2ECW), TRIM32 (2CT2), TRIM39 (2ECJ), TRIM31 (2YSL) and the TRIM37 
RING dimer (3LRQ), which is stabilized by a 4-helix bundle. The second RING monomer 
is shown in black and the Zn ions are shown as purple spheres. 
B-box 2 (red): Overlay of B-box 2 structures from human TRIM5α (2YRG), TRIM29 
(2CSV), TRIM54 (3Q1D), TRIM63 (3DDT) and the tandem B-box 1 (purple) - Box 2 
structure from TRIM18 (2JUN). The TRIM63 B-box 2 crystallized as a homodimer and 
the second monomer is shown in black. Zn ions are shown as purple spheres. 
Coiled-coil (blue): Structures of the TRIM5α B-box 2-coiled-coil (4TN3) and the TRIM25 
(4LTB) and TRIM69 (4NQJ) coiled-coils. Note the conserved antiparallel fold-back 
configuration of the coiled-coil-L2 linker region as well as variations in the overall 
curvature. 
PRYSPRY (orange): Structures of the rhesus TRIM5α PRYSPRY domain (2LM3, 3UV9, 
4B3N). The v1 hypervariable loop is disordered/deleted in the crystal structures and 
undefined in the NMR structure. 
CypA (green): Overlay of owl monkey TRIMCyp CypA domains in complex with HIV-1 





















(157). RING domains often dimerize to function (158), including the TRIM37 and 
TRIM5α RINGs (PDB IDs: 3LRQ and 4TKP). These dimers are stabilized by a four-helix 
bundle formed by two helices that flank the zinc-binding core, reminiscent of the BRCA1-
BARD1 RING heterodimer (159) (and Dmitri Ivanov, personal communication). As 
discussed further in Chapter 5, TRIM5 RING dimerization likely regulates its E3 ubiquitin 
ligase activity, and could, in turn, be regulated by B-box 2-dependent and capsid-dependent 
TRIM5 assembly (64). B-box domains are exclusive to the TRIM family and resemble 
RING domains structurally (160). B-box 2 domains can occur alone in TRIM proteins, but 
B-box 1 domains, when present, are always followed by B-box 2 domains. The tandem B-
box 1-B-box 2 structure is reminiscent of RING-RING heterodimers (161), but the roles of 
these tandem domains are unclear. The B-box 1 domain could regulate RING activation, 
or conceivably even possess E3 ligase activity, though there is no biochemical evidence 
for this activity. In the case of TRIM5, and perhaps in other self-assembling TRIM proteins, 
the B-box 2 mediates intermolecular interactions between TRIM dimers to form higher-
order oligomers (Section 1.6, Chapter 2 and (162, 163)). Other TRIM B-box 2 domains 
have been crystallized as dimers and the dimer interface involves the equivalent surface 
patch seen in TRIM5, but it is not yet known whether these isolated B-box 2 dimers are 
relevant for TRIM higher-order assembly or merely a crystallographic artifact (see Chapter 
5). 
PRYSPRY (B30.2) domains have canonical immunoglobulin folds, comprising two 
sandwiched β-sheets that present target binding loops at their edges. In the case of TRIM5α, 
these ‘hypervariable’ loops are positively-selected to bind retroviral capsids, including 




broad specificity of individual TRIM5α alleles suggests that these loops, especially the 
flexible v1 loop (Figure 1.5), may adopt different conformations to bind different capsids. 
Similar conformational heterogeneity has already been observed in crystal structures of the 
CypA domain of owl monkey TRIMCyp in complex with several CA constructs (166-168). 
HIV-1 CA is not recognized by the PRYSPRY domain of human TRIM5α, but 
interestingly, binding and restriction can be rescued by the deletion or Pro substitution of 
the v1 loop Arg332 residue (169, 170). 
 
1.6 TRIM5 protein assembly 
Mammalian host cells can be invaded by divergent retroviruses with highly variable 
capsid morphologies and dissimilar CA sequences, yet individual TRIM5α alleles can often 
recognize and restrict multiple different retroviruses (171). When a retroviral core is 
released into the cytoplasm of a cell that expresses a restrictive TRIM5α allele, the 
PRYSPRY domain of TRIM5α binds directly to the capsid surface, although the precise 
binding epitopes are only known for the TRIMCyp variant. The broad reactivity of TRIM5 
proteins reflects cooperative capsid binding. Evidence in support of this idea includes: (a) 
The affinity of the PRYSPRY domain for free HIV-1 CA dimers is undetectably weak in 
solution (172), suggesting that the RBCC domains can somehow augment capsid binding 
strength. (b) Fluorescence microscopy images of YFP-TRIM5α-expressing cells infected 
with mCherry-Vpr-labeled HIV-1 viruses reveal that multiple TRIM5 molecules coat 
invading viral cores. (c) Many TRIM family members, including TRIM5α, can 





These observations and our understanding of the capsid structure suggest that higher-
order TRIM5 multimers may assemble on viral cores, thereby creating avidity effects and 
facilitating PRYSPRY-recognition of repeating patterns on the capsid surface. Indeed, 
TRIM5α multimerization appears to be mediated by a hydrophobic patch on the TRIM5α 
B-box 2 surface, and this surface is required for HIV-1 restriction (162, 163). Our studies 
provide the first electron microscopic image of these TRIM5α self-assemblies (Chapters 2 
and 4 and ref. (154)). 
CypA-CA interactions are well-characterized (174), and unlike the PRYSPRY domain 
of TRIM5α, the CypA domain of TRIMCyp binds to cyclophilin-binding loops on 
monomeric CA proteins with measurable Kd values of 48-130 µM (166). As might be 
expected, B-box 2-mediated higher-order self-assembly is therefore less critical for 
TRIMCyp binding and restriction of HIV-1 (175, 176). Nevertheless, TRIMCyp self-
assembly may buffer against CA mutations that lower CypA affinities and also facilitate 
RING domain activation and downstream signaling, as described in the following sections 
(64, 166). The bigger question of how TRIM5 self-assemblies interact with the assembled 
capsid surface is still unsolved, but our progress so far is presented in Chapters 4 and 5. 
 
1.7 TRIM5 restriction mechanisms 
TRIM5α induces dissociation of susceptible capsids and also blocks reverse 
transcription (145), perhaps because reverse transcription requires proper capsid stability 
and uncoating (177). TRIM5-induced capsid disassembly requires both the RING E3 
ubiquitin ligase activity as well as proteasome function, and mutations in the RING domain 




transcription to proceed (Figure 1.4) (173, 178). The virus remains restricted under these 
experimental conditions, however, perhaps because the TRIM5-bound core is ‘trapped’ in 
TRIM5 cytoplasmic bodies and prevented from delivering the PIC into the nucleus (173). 
This explanation is supported by the observations that artificial multimers of CypA can 
potently block HIV-1 replication prior to nuclear import (179, 180). 
Posttranslational protein ubiquitylation mediates a series of important cellular events. 
In this process, the Ub C-terminus is activated by a Ub-activating (E1) enzyme and 
transferred to a ubiquitin-conjugating (E2) enzyme. Ubiquitin ligase (E3) enzymes like 
TRIM5α then help transfer the Ub either to the N-terminus or to a side chain Lys or Cys 
residue of a protein substrate. Substrates can either be different proteins, or Ub itself, which 
has 7 Lys residues (e.g., Lys63). Ub-Ub coupling results in the formation of poly-Ub 
chains, and the chain linkage typically dictates the biological readout (reviewed in (181, 
182)). 
In one current model for TRIM5 restriction (Figure 1.4), capsid binding activates the 
RING domain of TRIM5α to bind the heterodimeric E2 ubiquitin conjugating enzyme, 
Ubc13/Uev1A (also known as Ube2N/Ube2V1), and catalyze the synthesis of K63-linked 
poly-Ub chains that are not anchored to any substrate (64). These free Ub chains can be 
sensed by the Ub-specific adapters, TAB2 and TAB3, which in turn activates the TAK1 
kinase complex. TAK1 helps to establish an antiviral state by activating the NF-κB and 
AP-1 response pathways. Ubc13 and TAK1 are essential for TRIM5α-mediated block to 
reverse transcription (and for proteasome-dependent capsid disassembly), suggesting that 
these signaling events may somehow recruit the proteasome to the TRIM5-bound capsid. 




26A proteasome could remove CA subunits and thereby induce capsid dissociation. It is 
unclear, however, how free K63-linked poly-Ub chains could recruit the proteasome to the 
TRIM5-bound capsid, because (a) they are unanchored and therefore free to diffuse away 
from the site of restriction; and (b) canonical proteasome recruitment occurs in cells via 
K48-linked (rather than K63-linked) poly-Ub chains. 
A recent study has also indicated a role for directed autophagy in TRIM5-mediated 
capsid degradation (183). According to this study, TRIM5α binds p62/Sequestosome-1 
(SQSTM-1) and Beclin-1, which in turn recruit autophagosomes to degrade capsids in 
lysosomes. Indeed, p62 can bind and co-localize with TRIM5α in cells (184), and in other 
contexts, can serve as an adaptor that targets substrates to nascent autophagosomes as well 
as proteasomes (185, 186). It is presently unclear whether proteasome-mediated capsid 
dissociation and autophagosomal capsid degradation are mutually exclusive processes or 
complementary.  
Mechanistic insight into TRIM5 restriction could, in principle, be harnessed to design 
novel AIDS therapies. TRIM5 proteins likely block reverse transcription in a fashion 
analogous to capsid-weakening CA mutations, which trigger premature capsid dissociation 
(177). Human TRIM5α only weakly restricts HIV-1, if at all (72, 165, 170, 187). Therapies 
to introduce functional TRIM5 alleles have been demonstrated in cats and proposed in 
humans (188, 189), but gene therapy is expensive as well as inherently dangerous. An 
alternative approach would be to identify small molecules that modulate capsid stability in 
either direction ((51), and references therein). Indeed, such compounds (PF74, BI-1, BI-2) 
have already been identified, even if they do not precisely mimic TRIM5 proteins to 




affinity of human TRIM5α for HIV-1 capsids by acting as a ‘molecular glue’ at the 
TRIM5α-capsid interface, akin to auxin hormones in plants (191). 
Several outstanding issues remain in the TRIM field: (a) the conserved arrangement 
and strict ordering suggests that the RBCC motif functions as a single structural unit rather 
than as independently functioning modules. What is the the structural basis for this 
concerted action? (b) Most TRIM proteins can assemble into higher order cytoplasmic or 
nuclear structures called “TRIM bodies” (148). Similarly, TRIM5 proteins can assemble 
on incoming retroviral capsids, and these assemblies appear to be the functional form of 
the protein. What are the compositions, structures and functions of higher order TRIM 
assemblies? (c) What are the substrates and cognate E2 enzymes for TRIM-mediated 
ubiquitylation and SUMOylation, and how is TRIM E3 activity regulated? (d) What are 
the biological consequences of TRIM ubiquitylation? In the case of TRIM5 proteins, 
ubiquitylation somehow regulates innate immune signaling pathways such as type I and II 
interferon responses, activation of NF-κB, AP-2, IRF3 and IRF7 (65, 192, 193), yet the 
precise stepwise pathways are not known. (e) Finally, why do several autoimmune and 
hereditary disease phenotypes map to TRIM proteins, often in their C-terminal domains 
(136)?  
Structural and biochemical analyses that could, in principle, address many of these 
questions are challenging because TRIM proteins are difficult to purify and readily 
partition into insoluble self-assemblies when over-expressed or concentrated. In this 
dissertation, I describe how I have overcome these technical hurdles, studied the 
biochemical and assembly properties of TRIM5α, and proposed and validated a model for 




1.8 Overview of chapters 
The overall aim of my research was to determine how TRIM5 proteins recognize 
retroviral capsids. This goal has required me to: (a) develop methods to express and purify 
recombinant TRIM5 proteins, (b) study how they self-assemble and co-assemble on 
hexagonal CA lattices that mimic the surface of the HIV-1 capsid (in collaboration with 
Mark Yeager’s group), (c) image HIV-1 capsids decorated with TRIM5α using electron 
cryotomography (in collaboration with Yen-Li Li and Grant Jensen’s group) and (d) 
crystallize and attempt to determine the crystal structure of TRIM5 proteins, both alone 
and in complex with hexameric CA assemblies (in collaboration with Chris Hill’s and 
Owen Pornillos’s groups). 
The Appendix reports the first expression, purification and biochemical 
characterization of a recombinant TRIM5 protein, a restrictive variant of rhesus TRIM5α 
called “TRIM5-21R”. In this construct, the native rhesus TRIM5α RING domain was 
replaced with the RING domain of human TRIM21. This substitution increases the half-
life of the protein in mammalian and insect cells (194), and facilitates protein expression 
and purification in quantities sufficient for biochemical and EM studies. This study 
revealed that TRIM5-21R is a dimeric E3 Ub ligase that binds authentic equine infectious 
anemia virus (EIAV) capsids, as well as helical tubes of HIV-1 CA formed in vitro.  
Chapter 2 reports the discovery that TRIM5-21R dimers can spontaneously self-
assemble and co-assemble with 2D crystals of HIV-1 CA to form hexagonal lattices 
comprising open rings of TRIM5-21R. We proposed a model in which TRIM5 proteins 
recognize the “pattern” of the capsid surface by assembling hexagonal lattices that 




capsids. Such assemblies could position repeating PRYSPRY domains over their capsid 
surface epitopes, thus augmenting the weak intrinsic capsid affinities of TRIM5 PRYSPRY 
(and CypA) domains through avidity effects. 
The crystal structure of the TRIM25 coiled-coil/L2 linker domain is reported in Chapter 
3. (The X-ray crystallography was performed by the Pornillos lab.) I performed supporting 
biochemical experiments that revealed that this region of most TRIMs, including TRIM5α, 
form analogous antiparallel dimers. 
In the work reported in Chapter 4, we validated our “pattern recognition” model by 
directly visualizing hexagonal TRIM5α assemblies on the surfaces of purified HIV-1 core 
particles using cryoelectron tomography. To achieve this, I developed methods for 
expressing and purifying multimilligram quantities of several different primate TRIM5α 
proteins. 
In Chapter 5, I report my (unpublished) attempts to crystallize and determine the X-ray 
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PRIMATE TRIM5 PROTEINS FORM HEXAGONAL 
 NETS ON HIV-1 CAPSIDS 
 
4.1 Introduction 
Mammalian hosts have evolved a series of different innate immune strategies to combat 
retroviruses (reviewed in (1-3)). TRIM5α and the related TRIMCyp protein (collectively 
TRIM5) are restriction factors that recognize incoming retroviral core particles, induce 
their dissociation and inhibit reverse transcription (4-6). The mechanistic basis for core 
inactivation is not yet well established, but current models invoke the involvement of 
proteasomes (7-12), autophagosomes (13) and/or the establishment of a general antiviral 
state (14). Like other members of the tripartite motif (TRIM) family (15), TRIM5 proteins 
comprise a RING E3 ubiquitin (Ub) ligase domain (16, 17), an L1 linker, a B-box 2 self-
assembly domain (18), an antiparallel dimeric coiled-coil and an L2 linker that folds back 
on the coiled-coil (19-21) (Figure 4.1A). TRIM5 proteins also contain one of two different 
C-terminal viral recognition domains: a PRYSPRY (B30.2) domain in TRIM5α and a 
cyclophilin A (CypA) domain in TRIMCyp (5, 6, 22). 
TRIM5 proteins act by binding the outer capsid shell of the viral core replication 
particle. The capsid protects and organizes the internal nucleocapsid, which comprises the 







Figure 4.1 ECT analysis of TRIM5-21R 2D crystals. (A) Schematic of the TRIM5 dimer. 
The two RING (yellow) and B-box 2 (red) domains are separated by a ~17 nm, antiparallel 
dimeric coiled-coil (blue). The two L2 linkers (green) fold back towards the two-fold axis 
of the coiled-coil to orient two capsid-binding SPRY domains (orange). (B and C)  
Tomographic slice (top) of (B) full-length and (C) ΔSPRY lattices. Scale bars represent 
100 nm. In both cases, the computed Fourier transform (bottom, left) and subtomogram 
average without imposed rotational symmetry (bottom, middle) exhibits six-fold 
symmetry. Isosurface representations of the densities are also shown (bottom, right). (D) 
A density difference map of the subtomogram averages of full-length and TRIM5-
21RΔSPRY lattices reveals positive density (red) at the center of each hexagon edge, 
corresponding to the SPRY domain position, confirming the TRIM5α dimer model shown 
in (A). (E) Heat maps (bottom) of lattice arm lengths and angles measured from refined 
lattice points (top) selected from the TRIM5-21R tomogram in (B). (F) Histograms 
showing the distributions of measured arm lengths and angles. The most abundant arm 
length (18.5-19 nm) and arm angle (120°) are consistent with the structure model in (A) 








are constructed from several hundred CA protein hexamers and exactly 12 CA pentamers 
(24-30). Although all retroviral capsids are organized following these principles, individual 
capsids are unique, asymmetric objects that can differ in hexamer numbers and pentamer  
distributions. For example, HIV-1 capsids are typically conical, but their sizes and cone 
angles can vary, and cylindrical and spherical capsids also form (31, 32). Indeed, spherical 
and cylindrical capsids predominate in other retroviral genera, and capsid surface 
properties can vary considerably because CA proteins from different genera can share 
<10% sequence identity (24).  
To function effectively, individual TRIM5 proteins must overcome these variations in 
retroviral capsid shape and sequence (33). We, and others, have proposed that TRIM5 
proteins accomplish this by recognizing repeating patterns on the capsid surface (20, 23, 
34, 35). This model supposes that flexible loops on the PRYSPRY and CypA domains can 
adopt multiple different conformations and can bind weakly, but promiscuously, to 
conserved elements on the capsid surface (22, 35-40). These weak interactions are then 
amplified by TRIM5 assembly into a higher-order hexagonal lattice, which positions arrays 
of PRYSPRY/CypA domains to interact with repeating epitopes on the capsid surface (23, 
41). 
This “pattern recognition” model has been supported by biochemical and structural 
analyses of a TRIM5 protein construct called TRIM5-21R, which is an artificial chimera 
in which the RING domain from human TRIM21 replaced the RING domain of rhesus 
TRIM5α (42-44). This construct retains HIV-1 restriction activity, and was studied owing 
to its unusually favorable stability, solubility and assembly properties. Consistent with the 
pattern recognition model, TRIM5-21R was shown to assemble into open hexagonal 
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lattices, both alone and on the surface of 2D CA crystals that mimic the surface of the HIV-
1 capsid (23). Structural details were limited, however, because the hexagonal TRIM5-21R 
assemblies were reconstructed as 2D projections rather than 3D objects, domain positions 
were not identified experimentally, and the reconstructions were interpreted in the absence 
of any high resolution information on the structure of the TRIM5 protein core. The 
technical challenge of purifying authentic HIV-1 cores has also been another significant 
experimental limitation, and all published biochemical and structural studies of TRIM5α-
capsid interactions have therefore either employed crude viral core preparations or artificial 
mimics of the capsid surface (5, 23, 44-46). Thus, the interactions between authentic viral 
capsids and TRIM5 proteins have yet to be investigated biochemically or structurally. To 
address these shortcomings, we have developed methods for preparing authentic 
recombinant TRIM5 proteins and stable HIV-1 cores, and used these reagents to 
characterize how TRIM5 proteins recognize and assemble on HIV-1 capsids. 
 
4.2 Results 
4.2.1 Structure-based models for TRIM5-21R assembly 
We began our studies by defining the domain organization within the hexagonal 
TRIM5-21R lattice. TRIM5-21R spontaneously assembles into flat hexagonal lattices 
comprising open hexameric rings that are ~19 nm along each edge (corresponding to an 
inter-ring spacing of ~33 nm). Recently, several high resolution crystal structures have 
revealed that the TRIM coiled-coil has an antiparallel orientation and is ~17 nm long, 
suggesting that each hexamer edge is likely to be composed of a single TRIM5α dimer (19-
21). The ensuing L2 linker folds back against the coiled-coil and can form a four helix 
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bundle at the center of the coiled-coil, which could, in principle, serve as a “platform” that 
supports and orients the TRIM5α SPRY domains. However, direct structural information 
on the location of the SPRY domains within the hexagonal lattice has been lacking. 
To visualize TRIM5-21R assemblies in three dimensions and locate the positions of 
the SPRY domains, we generated electron cryotomograms (ECT) from tilt series of 
vitrified 2D crystals of both full length TRIM5-21R (Figure 4.1B) and a construct that 
lacked the SPRY domain (TRIM5-21RΔSPRY, residues 1-300, Figure 4.1C). The 3D 
reconstructions were then refined and improved by subtomogram averaging of densities 
centered at equivalent lattice vertices (see Figure 4.1 caption, and Experimental Methods). 
As expected, TRIM5-21R and TRIM5-21RΔSPRY both assembled into similar planar lattices 
of hexagonal rings, whose inter-ring spacings and protein densities matched those of the 
previous 2D projection structures (23). As shown in Figure 4.1D, difference density maps 
clearly revealed that the SPRY domains reside at the center of each hexagon edge. We 
therefore conclude that the edge of each TRIM5-21R ring is a dimer, with the overall 
domain organization shown in Figure 4.1A. 
 
4.2.2 The TRIM5-21R lattice is hexagonal net with variable arm 
 lengths and angles 
Although the paracrystalline arrays of TRIM5-21R exhibited long-range order, 
individual hexamers within the lattice appeared to vary in shape and size. This variability 
was quantified by a nearest neighbor analysis of the refined positions of lattice vertices 
used for subtomogram averaging.  The relative positions of 153 vertices in the 2D crystals 
of TRIM5-21R were used to define individual hexamer edge lengths and angles (see Figure 
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4.1E). The length distribution of hexamer edges was centered about a mean of 19 nm, but 
individual edge lengths varied by up to ±5 nm (Figure 4.1F, upper panel). Similarly, the 
distribution of hexamer vertex angles was centered about 120°, but varied by up to ±20°. 
These ranges likely underestimate the actual range of hexamer variability owing to the 
initial selection of well-ordered lattice points. Thus, the hexagonal TRIM5-21R lattice is 
neither highly regular nor rigid, but is rather best described as a paracrystalline “net”, 
within which individual rings can exhibit considerable conformational variability. 
 
4.2.3 Expression and purification of authentic primate TRIM5α  
and TRIMCyp proteins 
Recombinant TRIM5α proteins are difficult to express and purify owing to their 
propensity to self-assemble, both in cells and in vitro. All previous biochemical and 
structural studies of TRIM5α proteins have therefore been performed with impure proteins 
or with protein fragments or nonnative chimeric constructs. To overcome this limitation, 
we tested a variety of different expression and purification conditions, with the goal of 
developing a general method for preparing multimilligram quantities of authentic, full-
length primate TRIM5α and TRIMCyp proteins.  
The strategy that was ultimately successful entailed expressing TRIM5 proteins in 
insect cells using a baculoviral expression system. As described in the Experimental 
Methods, expressed TRIM5 proteins formed cytoplasmic bodies that could be solubilized 
by lysing the cells in a low ionic strength, alkali buffer that contained the nonionic 
detergent, Triton X-100, as well as a nondetergent small molecule, sulfobetaine-256 
(NDSB-256) that has previously been shown to inhibit protein aggregation (47, 48). Once 
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solubilized, primate TRIM5 proteins typically remained dimeric and soluble under low 
salt, alkaline conditions in the absence of Triton X-100 and NDSB-256, even at 
concentrations greater than 1 mg/ml. The proteins could therefore be purified, provided 
they were maintained at high pH, low salt and/or low protein concentrations.  
Our stepwise protein purification protocol is illustrated for rhesus TRIM5α in Figure 
4.2A. Briefly, N-terminal OneSTrEP-FLAG- (OSF-) or C-terminal FLAG-OneSTrEP-
(FOS-) tagged TRIM5 proteins were initially purified using Strep-Tactin affinity 
chromatography, the affinity tag was removed by PreScission protease treatment and the 
proteins were then purified to homogeneity by anion exchange and gel filtration 
chromatography. Analogous approaches were used to express and purify wild type and 
mutant TRIM5α proteins from rhesus macaques (Macaca mulatta, here abbreviated 
TRIM5αrh), African green pygerythrus monkeys (C. pygerythrus, TRIM5αAGMpyg), 
chimpanzees (P. troglodytes, TRIM5αCPZ), humans (H. sapiens, TRIM5αhu) and the 
TRIMCyp protein from owl monkeys (A. trivirgatus, TRIMCyp). Yields ranged between 
1.3 and 9.6 mg/L of insect cell cultures, and all of the proteins eluted with similar retention 
times during the final gel filtration chromatography step, indicating that they were all 
dimers of similar shape. All of the proteins could be purified to >95% purity (Figure 4.2B) 
with the exception of TRIMCyp, where our preparations also contained breakdown 
contaminants that mapped to proteoytic cleavage at residues Lys283 and Gln287 (not 
shown). These breakdown contaminants were eliminated by creating a mutant construct 
that expressed TRIMCypK283D,Q287D (lane 10). These mutations are not expected to affect 
other relevant properties of the protein because TRIMCypK283D,Q287D retains potent HIV-1 
restriction activity (see Figure 4.3). 
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Figure 4.2. Purification and characterization of recombinant TRIM5 proteins. (A) 
Coomassie-stained SDS-PAGE showing the stepwise purification of rhesus TRIM5α 
(TRIM5αrh). Samples correspond to: soluble lysate from control SF9 cells (Uninfected, 
lane 1); soluble lysate from SF9 cells expressing OSF-TRIM5αrhesus (Infected, lane 2); 
StrepTactin affinity-purified OSF-TRIM5αrhesus (Affinity, lane 3); ΔOSF-TRIM5αrhesus 
after PreScission protease treatment (Tag Cleavage, lane 4); dimeric TRIM5αrhesus purified 
by Q anion exchange chromatography (Anion Exchange, lane 5); dimeric TRIM5αrhesus 
purified by Superdex 200 gel filtration chromatography (Gel Filtration, lane 6). (B) 
Coomassie-stained SDS-PAGE showing 1.5 µg of purified dimers of rhesus, African green 
monkey pygerythrus (AGMpyg), chimpanzee TRIM5α, proteolysis resistant owl monkey 
TRIMCypK283D,Q287D, human TRIM5α, HIV-1-restrictive human TRIM5αR332P. (C, D) 
TRIM5 hexagonal assembly is a conserved feature. Negatively-stained EM image of a 
hexagonal array formed by (C) dimeric TRIM5αAGMpyg and (D) TRIMCyp. Computed 
Fourier transforms (top right insets) show obvious hexagonal order. Projection density 
maps (with no imposed symmetry) of two-dimensional crystals preserved in vitreous ice 
(bottom left insets) also reveal hexagonal rings and density distributions reminiscent of 
TRIM5-21R lattices (23). The unit cell parameters are a = 345 Å, b = 345 Å, γ = 120° 
(TRIM5αAGMpyg); and a = 345 Å, b = 344 Å, γ = 119° (TRIMCyp). Note that the TRIMCyp 
samples contained a mixture of full-length TRIMCyp and fragments that were proteolyzed 
to the C-terminus of residues K283 or Q287 (see Results and Materials and Methods for 
details). The relatively thinner two-fold density in the TRIMCyp projection map could 
either be caused by low crystal occupancy of the CypA domain (due to proteolysis) or by 


















Figure 4.3 HIV-1 CA restriction activity of different alleles of TRIM5 proteins.  
HeLa-M cells were transiently transfected with vectors expressing TRIM5αhuman, 
TRIM5αCPZ, TRIM5αAGMpyg, TRIM5αrhesus, TRIMCyp, TRIMCypK283D,Q287D and empty 
vector control. Cells expressed TRIM5 proteins at approximate similar levels as verified 
by western blotting with α-TRIM5α antibody (right) and were transduced with VSV-G 
pseudotyped HIV-GFP reporter virions (left). The percentage of infected cells (GFP 
positive cells) was determined by FACS. As expected, TRIM5 proteins from AGMpyg, 
rhesus, owl monkey restricted HIV-1 whereas human and chimpanzee TRIM5 did not. The 
proteolysis-resistance mutations (K283D, Q287D) in TRIMCyp did not affect restriction 









4.2.4 Conservation of hexagonal TRIM5 protein assembly 
To determine whether the ability to assemble hexagonal nets is conserved, we screened 
for conditions that promoted assembly of the different primate TRIM5 proteins, using 
negative stain EM imaging to assay assembly states. These screens identified conditions 
under which two of the proteins, TRIM5αAGMpyg (Figure 4.2C) and TRIMCyp (Figure 
4.2D) spontaneously formed 2D hexagonal assemblies that were similar in appearance to 
those formed by TRIM5-21R. Unstained, vitrified 2D crystals of TRIM5αAGMpyg and 
TRIMCyp were imaged and processed to generate Fourier-filtered 2D projection 
reconstructions without any imposed symmetry (Figure 4.2C, D; bottom). Both proteins 
formed lattices comprising open hexameric protein rings that were similar in appearance 
and size to the TRIM5-21R rings, demonstrating that native TRIM5 proteins from highly 
diverged primates (with ~74% pairwise identities across the B-box 2, coiled-coil and L2 
linker regions) share the ability to assemble into analogous hexagonal nets. 
 
4.2.5 Templated hexagonal TRIM5 protein assembly on HIV-1  
CA surfaces 
The pattern recognition model for retroviral restriction predicts that binding to the 
surface of the viral capsid will promote hexagonal TRIM5 assembly. We therefore tested 
whether 2D crystals of HIV-1 CA, which mimic the capsid surface, could promote the 
assembly of three different TRIM5 proteins that can restrict HIV-1; TRIM5αrh, TRIMCyp 
and TRIM5αhu,R332P, and two different TRIM5 proteins that cannot restrict HIV-1; wild 
type TRIM5αhu and TRIM5αcpz. To test for templated assembly, soluble dimeric TRIM5 
proteins were incubated together with preassembled 2D CA crystals under solution 
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conditions that were sufficiently stringent to prevent untemplated assembly. 
TRIM5αAGMpyg was not used in these studies because it assembled very robustly even in 
the absence of a template. 
As shown in Figure 4.4, the three TRIM5 proteins assembled into visible hexagonal 
nets on the surfaces of preformed HIV-1 CA crystals, whereas template assembly was not 
observed for either of the nonrestricting TRIM5 proteins. Templated assembly therefore 
correlated well with restriction activity, emphasizing the coupling of CA binding and 
TRIM5 assembly. Computed Fourier transforms of the images of decorated crystals 
(Figure 4.4, insets) revealed well-defined first- and second-order reflections from the 
smaller underlying CA lattice (red and blue), as well as more diffuse peaks (TRIM5αrhesus 
and TRIMCyp, green) or a powder diffraction ring (TRIM5αhu,R332P) that corresponded to 
the first-order reflections of the hexagonal TRIM5 lattices. Thus, all three restricting 
TRIM5 proteins bound the CA surface and assembled into hexagonal nets that were clearly 
visible, but lacked extensive long-range order. 
 
4.2.6 Generation of hyperstable, disulfide-crosslinked HIV-1 core 
 particles 
The helical tubes formed by pure recombinant HIV-1 CA provide another regularized 
model for the curved, but less symmetrical arrays of CA hexagons displayed on the viral 
capsid surface [REF]. We employed a previously described sucrose cosedimentation assay 
to test whether the restricting TRIM5αAGMpyg and TRIMCypK283D,Q287D proteins bound the 
disulfide-crosslinked helical tubes formed by the HIV-1 CAA14C,E45C protein. As shown in 











Figure 4.4 Assembly of restricting TRIM5 proteins on 2D crystals of HIV-1 CA. Negative 
stained EM image of CA co-crystals with (A) TRIM5αrhesus, (B) TRIM5αhuman,R332P, (C) 
TRIMCypK283D,Q287D. Scale bars represent 100 nm. Computed Fourier transform (inset) and 
indexing (second inset) show the first- and second-order reflections of two CA lattices and 
their unit cell parameters (red and blue) as well as diffraction spots (A, C) or rings (B) 









Figure 4.5 TRIM5 protein binding to hyperstable HIV-1 CA tubes. (A) (left) Binding 
experiments were performed using either wild type, full-length TRIM5αAGMpyg (Wild 
Type, lanes 1, 2) or truncated TRIM5αAGMpyg that lacked the SPRY domain (ΔSPRY, lanes 
3, 4), in the absence of CA tubes (lanes 1, 3) or in the presence of CA tubes (lanes 2, 4) . 
Pelletable CA and associated TRIM5αAGMpyg (Pellet, 30% in total), were separated from 
unassembled and soluble CA proteins and unbound TRIM5αAGMpyg (Supernatant, 3% in 
total) by centrifugation, and analyzed by Western blotting, with the input levels of both 
proteins shown for reference (Input, 3% in total). (right) Similar experiments were 
performed using proteolysis-resistant TRIMCypK283D,Q287D in the absence (lane 5) or 
presence (lanes 6, 7) of helical CA tubes, without (lanes 5, 6) or with added CsA (lane 7), 
a specific inhibitor of the CypA-CA interaction. Lane 8 is a CA tube control, with no added 
TRIMCypK283D,Q287D or CsA. (B) Representative electron micrographs of control CA tubes, 
TRIM5αAGMpyg and TRIMCypK283D,Q287D decorated tubes negatively stained with uranyl 
acetate (UA) or phosphotungstic acids (PTA). Scale bar represents 50 nm. (C) Histograms 
showing the distributions of measured inter-ring spacings (n=180). The most abundant 
inter-ring spacing (30-35 nm) is consistent with the spacing of TRIM5-21R 2D crystals, 
indicating the observed rings are correct size. (D) Deep-etch electron micrographs of 
control tube (top) and TRIM5α decorated CA tubes (bottom) with a blow-up view of boxed 

















through the gradient when the CA tubes were present, but not when they were absent 
(compare the “pellet” fractions in lanes 1 and 2 and lanes 5 and 6). Binding was specific 
because TRIM5αAGMpyg did not cosediment with CA tubes when the SPRY domain was 
removed (compare lanes 2 and 4) and because TRIMCyp binding to CA tubes was 
abolished in the presence of cyclosporine A, which competitively inhibits the CypA-CA 
interaction (compare lanes 6 and 8). Thus, these pure recombinant TRIM5 proteins also 
bind the curved hexagonal lattices of helical CA tubes. 
Negative stain and deep etch electron microscopy approaches were used to image the 
TRIM5-decorated HIV-1 CA tubes. TRIM5 proteins formed thin ring-like decorations on 
the surfaces of CA tubes (Figure 4.5B). These decorations appeared as light, string-like 
nets against the darker underlying CA tubes when either uranyl acetate (UA) or 
phosphotungstate was used as the stain. No equivalent decorations of control CA tubes 
alone were seen in either case. The most common inter-ring spacing in the TRIM5αAGMpyg 
samples was 30-35 nm, in excellent agreement with the other measurements of the TRIM5 
hexagonal lattice, although the rings were again irregular and inter-ring spacings varied 
between 20 and 55 nm (Figure 4.5C). 
Deep etch EM images can often exhibit even greater contrast than negative stained 
transmission EM images, and this was evident even in deep etch images of undecorated 
HIV-1 CA tubes, where rows of invididual CA hexamers were readily visible (Figure 4.5D, 
upper row). Strings and rings of TRIM5αAGMpyg were often also more visible on the 
decorated CA tube surfaces, and networks of rings were clearly observable in some cases 
(Figure 4.5D, lower panel). We therefore conclude that TRIM5 proteins can also form 
hexagonal nets on the surfaces of helical HIV-1 CA tubes. 
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4.2.7 Generation of hyperstable, disulfide-crosslinked HIV-1 core  
particles 
A central goal of our studies was to analyze TRIM5 binding to authentic viral capsids, 
both biochemically and by direct imaging. This goal is technically challenging owing to 
the inherent instability of viral core particles. We reasoned that this challenge might be 
overcome by disulfide crosslinking the capsid shell to increase stability. This strategy was 
particularly attractive because our previous studies have shown that Cys residues 
substituted at CA positions Ala14 and Glu45 crosslink efficiently when CA hexamers are 
assembled in vitro (28, 49). We therefore tested the effect of introducing these substitution 
mutations into HIV-1 virions.  
Normal levels of viral particles were produced from 293T cells that expressed an HIV-
1NL4-3∆R8.2 proviral expression vector encoding the mutant CAA14C,E45C protein (not 
shown). Wild type and mutant viral cores were isolated by spinning virions through a 
detergent layer to remove the outer viral membrane and then directly into a 30-70% sucrose 
gradient, where viral cores concentrated at a density of 1.22-1.27 g/ml (fractions 10-12, 
highlighted in pink in Figure 4.6A, left panel) (50). As reported previously (50, 51), wild 
type cores can be isolated using this procedure (see Figure 4.6B), but the yields of 
recovered cores were consistently low in our hands (0.2±0.1% based upon total virion CA). 
This was apparently because most of the CA molecules dissociated from the core and 
migrated to the top of the gradient during purification (Figure 4.6A, left panel). In contrast, 
nearly all of the CAA14C,E45C  protein migrated toward the bottom of the gradient when cores 
were isolated from mutant virions (Figure 4.6A, right panel). The bulk of this CA protein 
was present within small incomplete/broken or spherical assemblies that concentrated at  
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Figure 4.6 Purification of wild type and hyperstable HIV-1 cores. (A) Wild type (left) and 
hyperstable A14C/E45C (right) HIV-1 cores were purified using a sucrose-gradient “spin-
through” method (50). Sucrose gradient profiles showing α-CA western blots of sucrose 
gradient fractions (top) as well as quantified CA levels (bottom) and density (bottom blue 
line; g/ml) of each gradient fraction. The migration of the CA peak to denser fractions 
clearly demonstrated the higher stability of crosslinked HIV-1 cores (compare the amounts 
of wild type and A14C/E45C CA in fractions 10-12). Fractions corresponding to the 
expected core densities (10-12) are highlighted in pink and were pooled, washed and 
concentrated for the analyses in B and C. (B) Negatively stained electron micrograph of 
wild type (left) and A14C/E45C (right) cores shows apparently normal conical, cylindrical 
and spherical cores. Note the presence of contaminating detritus in the background 
(introduced by commercial sucrose stocks). Pie charts (inset) of observed morphologies of 
wild type (left; n = 143 cores) and A14C/E45C cores (right; n=353 cores) show that the 
introduced Cys crosslinks do not alter HIV-1 core morphologies significantly. (C) 
Nonreducing α-CA western blots showing that A14C/E45C cores are crosslinked (compare 
% hexamer as a function of [β-ME]). Asterisks indicate Gag fragments (p55 and p37) that 
copurifed with mature cores during purification. (D, E) Representative negatively stained 
electron micrographs showing the relative abundance and purity of (D) A14C/E45C 
crosslinked cores and (E) A14C/E45C crosslinked cores with an additional A92E mutation 
that reduces core clustering (right) (31, 52). Scale bar represents 100 nm. The higher yield 
of crosslinked cores and the absence of contaminants or core clustering in the affinity 






densities of 1.18-1.21 g/ml (gradient fractions 6-9, Figure 4.6A, right panel and see Figure 
4.7). These nonnative assemblies probably arise from spurious crosslinking of CA 
hexamers in the free intraviral pool of CA molecules that are excluded from the mature 
HIV-1 capsid (53-55). Nevertheless, a substantial fraction of the CA protein also 
concentrated at the density expected for native core particles (fractions 10-12, highlighted 
in pink in Figure 4.6A, right panel). These “hyperstable” cores were reproducibly 
recovered in higher yields than wild type cores (0.8±1%) and their distribution of  
morphologies was similar to that of wild type cores (Figure 4.6B, right panel). Consistent 
with the experimental design, nearly all of the CA molecules within these fractions were 
crosslinked within stable hexamers, as analyzed by nonreducing SDS-PAGE and western 
blotting (Figure 4.6C). These experiments indicate that disulfide crosslinks form 
spontaneously in otherwise native and untreated HIV-1 capsids, and that the crosslinks 
stabilize the capsids without introducing any major morphological defects. 
 
4.2.8 Isolation of HIV-1 core particles for cryoEM imaging 
Sucrose gradient-purified hyperstable HIV-1 cores were suboptimal for imaging 
studies because they copurified with vesicles and other impurities and because they 
clustered together. To produce purer cores, we designed an alternative core affinity 
purification method that exploited the interaction between cyclophilin A (CypA) and HIV-
1 CA (outlined in Figure 4.7) (56-58). Briefly, viral membranes were stripped using a brief 
Triton X-100 treatment and the liberated cores were then captured on magnetic Strep-
Tactin beads derivatized with OSF-CypA. The immobilized cores were washed rigorously 








Figure 4.7 CA assemblies in fractions 7-9 are also composed of crosslinked hexamers. (A) 
Nonreducing α-CA western blots of CA assemblies in fractions 7-9. (B) Representative 
negative stain electron micrograph of fractions 7-9. (C) Pie chart of the observed 
morphological distribution of particles in fractions 7-9. (D) Purification schematic (refer 
to figure legend on the right.) Pure, recombinant OneSTrEP-FLAG-CypA (OSF-CypA) is 
added to HIV-1 virions and their limiting membrane is dissolved by detergent treatment. 
OSF-CypA-HIV-1 core complexes are captured using Strep-Tactin sepharose magnetic 
beads. The beads are restrained using a magnet and vesicles and other bound contaminants 
are removed by rigorous washing. Cores (but not CypA) are eluted by addition of 
cyclosporine A. (E) α-CA (top) and α-FLAG (CypA; bottom) western blot of samples from 
different steps in HIV-1 core affinity purification (see Experimental Procedures for 
details). Note that the eluate, which contains purified cores, is free from bound CypA and 
therefore suited for TRIM5α binding studies. (F) Silver-stained SDS-PAGE reveals that 

















inhibits the CypA-CA interaction and binds CypA ~700-fold more tightly than does CA 
(Figure 4.6D) (59-63). This method increased core yields an additional four-fold (3±2% 
core recovery) and dramatically increased their purity (compare Figure 4.6D to Figure 
4.6B, right panel). 
To reduce core clustering, we introduced a CA Ala92Glu substitution within the 
exposed loop of HIV-1 CA. This mutation does not affect TRIM5α restriction (64), and it 
was previously shown to reduce the clustering of helical CA tubes, presumably by reducing 
the overall surface hydrophobicity (31, 52). As shown in Figure 4.6E, the substitution also 
reduced the clustering of viral cores (compare Figures 4.6D and 4.6E), and did so without 
altering core morphology or reducing core yields (3±1% core recovery).  
In summary, hyperstable CAA14C,E45C,A92E cores could be purified by affinity 
chromatography and isolated in high yields. The purified cores contained the expected viral 
proteins as analyzed by silver staining (Figure 4.7), were hyperstable and fully disulfide 
crosslinked, exhibited normal capsid morphologies and spread diffusely on EM grids. 
 
4.2.9 TRIM5 binding to HIV-1 capsids 
The susceptibility of different retroviruses to restriction by different TRIM5 alleles can 
vary dramatically and appears to be determined at the level of capsid recognition (5, 22, 
64, 65). Consistent with previous reports (4, 6, 66), we found that TRIM5 proteins 
restricted the transduction of HeLa cells with an HIV-1 reporter vector following the order: 
TRIMCyp and TRIMCypK283D,Q287D>TRIM5αrh>TRIM5αAGMpyg>TRIM5αCPZ and 
TRIM5αhu (Figure 4.3). A sucrose cushion cosedimentation assay was again used to test 
whether our pure recombinant TRIM5α proteins bound directly to hyperstable HIV-1 
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cores, and whether core binding correlated with restriction activity. These experiments 
were performed with two proteins that restrict HIV-1; TRIM5αAGMpyg and TRIM5αrh, and 
one protein that does not restrict HIV-1; TRIM5αCPZ. Human TRIM5α proteins were not 
used in these assays because they tended to aggregate and pellet, even in the absence of 
HIV-1 cores. TRIMCyp was also not used, owing to the presence of low levels of residual 
cyclosporine A in the core preparations. 
As shown in Figure 4.8, the restricting TRIM5αAGMpyg and TRIM5αrh proteins both 
bound hyperstable HIV-1 cores as evidenced by the fact that these proteins copelleted with 
cores through the sucrose cushion, but did not pellet in the absence of cores (compare lanes 
1 and 2 and lanes 3 and 4). In contrast, the nonrestricting TRIM5αCPZ protein did not bind 
cores under similar conditions (compare lanes 5 and 6). The core binding experiments were 
performed in the presence of excess TRIM5α proteins, and the stoichiometry of the pelleted 
core-TRIM5αAGMpyg complexes was estimated by comparing the levels of CA and 
TRIM5αAGMpyg to standard curves of known protein concentrations. The measured 
TRIM5αAGMpyg:CA ratio in these experiments was 1:7±2 (n=4). Based upon the relative 
sizes, we estimate that each TRIM5 ring will cover ~14 CA hexamers (23). Based upon the 
known stoichiometries of each ring (CA=6, TRIM5α=6), we therefore estimate that a fully 
saturated capsid would have a TRIM5:CA ratio of approximately 1:14. Our experiments 
therefore indicate that two different restricting TRIM5α proteins can bind directly to 
hyperstable HIV-1 cores in vitro at near-saturating levels, whereas the nonrestricting 












Figure 4.8 TRIM5α proteins bind directly to HIV-1 cores and binding correlates with HIV-
1 restriction susceptibility. TRIM5 proteins were incubated in the absence of cores (lanes 
1, 3, 5) or in the presence of stable HIV-1 cores (lanes 2, 4, 6). Sucrose cushion 
centrifugation binding experiments were performed and pelletable cores and bound 
TRIM5α (Pellet, 30% of total) and unbound TRIM5α (Supernatant, 2% of total) were 
analyzed by western blotting for TRIM5 and CA proteins. The input levels of both proteins 
are also shown for reference (Input, 2% of total). Representative results from one of three 











4.2.10 EM Imaging of TRIM5 decorated HIV-1 cores 
Hyperstable cores were visualized in three dimensions (Figure 4.9) by electron 
cryotomography (ECT). Spherical, cylindrical and conical cores were observed displaying 
the same general size and lattice features expected of authentic HIV-1 cores (Figure 4.9). 
Holes in the tips of conical cores were also seen, supporting previous results suggesting 
that cores are frequently unclosed (67). 
We next imaged cores decorated with TRIM5αrh. In addition to the cores, the most 
prominent feature in the images was a network of densities at the air/water interface. The 
network exhibited three-fold vertices (Supplemental Movie 1) in the plane of the interface 
that were strikingly similar to 2D hexagonal TRIM5α lattices. Approximately 12% of cores 
imaged were also decorated on their outer capsid surfaces with TRIM5αAGMpyg densities. 
Multiple extended density "arms" approximately 19 nm in length were seen arranged in an 
approximately hexameric pattern (Figure 4.10, and Supplemental Movie 1). 
Because there was so much TRIM5αAGMpyg at the air/water interface, but only a small 
fraction of the cores were decorated with TRIM5α, we suspected that previously core-
bound TRIM5α was being lost to the air/water interface during plunge-freezing. To address 
this issue, we crosslinked the core/TRIM5α complexes with ethylene glycol 
bis(sulfosuccinimidylsuccinate) (Sulfo-EGS) prior to plunge freezing. There was still a 
substantial amount of TRIM5α at the air/water interface under these conditions, but now 
the majority of cores, including spherical, cylindrical and conical shaped ones, were 
decorated with TRIM5αAGMpyg.  Analysis of the volume surrounding these cores revealed 
broken, but extensive TRIM5a hexagonal nets and in some cases these nets enveloped the 











Figure 4.9 ECT of stable HIV-1 cores reveals structural features expected of HIV-1 cores. 
(A, B) Tomographic slices of two conical HIV-1 capsids, displaying no densities above 
background noise around their exterior. (C, D) Tomographic slices of NAD-filtered cores 
display side- and front-facing views of individual CA hexamers. Boxed in black and 
blown-up are densities with dimensions similar to those of the crystal structure of the HIV-
1 capsid. (E) Crystal structure of the HIV-1 capsid hexamer, the dimensions match those 
























Figure 4.10 ECT reveals that TRIM5α forms flexible hexagonal nets on hyperstable HIV-
1 cores. (A) Segmentation of a spherical HIV-1 core (yellow) decorated with TRIM5α 
(blue). (B) Two views of segmentation of a cylindrical HIV-1 core decorated with TRIM5α 
and subjected to mild sulfo-EGS crosslinking prior to vitrification. (C) segmentation of a 
conical HIV-1 core decorated with TRIM5α (sulfo-EGS crosslinked). (D) The same core 
as in (C) with the TRIM5α omitted. (E) Schematic model of an HIV-1 fullerene cone bound 

















Our studies strongly support the prevailing models that TRIM5 restriction factors bind 
directly to the surfaces of incoming retroviral capsids and that restriction susceptibility is 
dictated at the level of capsid recognition (4, 22, 37, 68, 69). We further find that the ability 
to assemble into hexagonal nets comprising open, six-sided rings is a conserved feature of 
multiple different primate TRIM5 proteins. Our EM analyses, together with recent crystal 
structures of fragments of nonassembling TRIM5 protein that span the core coiled-coil and 
L2 linker regions (20), indicate that each ring edge is formed by a TRIM5 dimer that 
displays two PRYSPRY (or CypA) recognition domains at its center. Most importantly, 
we find that capsid binding and TRIM5 assembly are coupled processes that collaborate to 
promote the recognition of pleomorphic retroviral cores with high affinity and specificity. 
 
4.3.1 Reagent development 
Through the course of our studies, we developed and characterized two new sets of 
reagents for studying retroviral replication and restriction: hyperstable, disulfide-
crosslinked HIV-1 capsids and pure recombinant primate TRIM5 proteins. The generation 
of hyperstable capsids was enabled by previous studies showing that Cys residues at CA 
positions 14 and 45 form disulfide bonds efficiently in vitro when these residues are closely 
juxtaposed within the CA hexamer (28, 49). Our experiments demonstrate that these 
disulfides also form efficiently in the context of the intact HIV-1 capsid. A similar disulfide 
crosslinking strategy was used to link CA trimers at cysteine positions 207 and 216 across 
the local three-fold axes of the HIV-1 capsid (70). We have compared these two different 
systems, as well as an alternative strategy in which CA hexamers were crosslinked by 
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disulfide bonds between Cys residues at CA positions 42 and 54 (49). Disulfide bonds form 
readily within viral capsids in all three cases (28, 49, 70) (and data not shown), and we 
anticipate that the different crosslinking strategies will have distinct advantages depending 
upon the application. For example, we have confirmed the report that HIV-1 cores with 
trimerized CA proteins retain modest infectivity (70), whereas infectivity is almost 
completely abolished when cores are crosslinked at either site in the CA hexamer. We also 
find, however, that viral core yields and stabilities are greater for the two hexamer 
crosslinking systems, and are highest for the Cys14/Cys45 system described here. Thus, 
these hyperstable capsids should be optimal for analyzing the binding of proteins and 
drugs, and we note that a series of HIV-1 capsid binding proteins have recently been 
described, including CPSF6 (71, 72), Nup153 (73-75) and Nup358 (75, 76), as have several 
capsid binding inhibitors, including PF-74 (77) and BI-1 and BI-2 (78). Hyperstable 
capsids may also represent a useful starting point for the development of in vitro viral 
replication assays, particularly if the capsid disulfides can be reduced without inactivating 
the internal reverse transcriptase and integrase enzymes. 
The development of systems for producing multimilligram quantities of pure 
recombinant primate TRIM5 proteins should similarly facilitate studies of restriction by 
enhancing methods for protein detection and enabling new mechanistic and structural 
analyses. For example, our recombinant TRIM5αrh proteins have already been used 
successfully as antigens to generate monoclonal antibodies that can detect endogenous 
TRIM5α proteins (NIH AIDS Reagent Program, and Tom Hope, personal communication). 
Moreover, although structural studies of TRIM5 protein domains and fragments have made 
valuable contributions to our understanding of TRIM5 structure and enzymology, there are 
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a number of indications that the different domains work together as an integrated machine. 
It will therefore also be important to study intact TRIM5 proteins, particularly to determine 
how capsid recognition is coupled to ubiquitin signaling (14).  
 
4.3.2 TRIM5 recognition of retroviral capsids and its implications 
 for restriction 
Antiviral innate immune factors that function by recognizing retroviral capsids must 
overcome considerable sequence and structural variability. Primate TRIM5 proteins 
accomplish this task by coupling weak recognition of conserved capsid epitopes with 
hexagonal net assembly, thereby amplifying intrinsically weak binding affinities through 
avidity effects. Our studies confirm the conservation of hexagonal net assembly, but also 
reveal that TRIM5 hexagonal nets are not highly regular. The lack of strict regularity in the 
TRIM5 net may be an adaptation to the opposing lack of regularity in retroviral capsids, 
where every CA hexagon occupies a slightly different local environment and pentagons 
and other kinds of lattice “defects” are also prevalent (67).  
Consistent with a lattice assembly model, imaging studies have provided direct 
evidence that multiple TRIM5 molecules can bind continuously to incoming capsids, (10). 
The stoichiometry of TRIM5-capsid interactions within cells is not yet known, but we find 
that TRIM5 molecules can cover most of the capsid surface in vitro. However, a patch of 
just 4-6 TRIM5 rings covers about half of the capsid surface (see Figure 4.10), and would 
present ~40 recognition domains for avid capsid binding. Thus, there is no reason to believe 
that the entire capsid must be completely enveloped within a surrounding TRIM5 lattice 
for restriction to occur. Indeed, CA mixing studies have shown that efficient TRIM5 
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restriction can occur even when only 25% of the capsid subunits are competent for TRIM5 
binding (79). 
TRIM5-mediated restriction appears to proceed via a multistep pathway in which 
capsid recognition is followed by steps that lead to capsid dissociation and inhibition of 
reverse transcription (5, 14). In cells, the later processes can be decoupled from the initial 
binding event by treatment with proteasome inhibitors or by mutations in the RING domain 
(8, 80). These treatments do not block TRIM5 binding, but presumably do interfere with 
ubiquitin-mediated signaling events. Thus, although TRIM5 binding can destabilize helical 
CA tubes in vitro (45, 46), capsid destabilization and inhibition of reverse transcription 
appear to require ubiquitin-dependent signaling in cells. Capsid binding can activate 
TRIM5 ubiquitin E3 ligase activity in vitro (14), and the structure of the hexagonal TRIM5 
lattice suggests how this could occur.  Recent structural studies of the RING domains from 
TRIM37 (PDB ID: 3LRQ) and TRIM5α (D. Ivanov, personal communication) have 
demonstrated that the RING domains function as dimers. However, the antiparallel 
structure of the TRIM5 coiled-coil precludes close contact of the two RING domains within 
a single TRIM5 dimer (19, 20). Thus, RING domains from multiple different TRIM5 
dimers must presumably come together to transfer ubiquitin, and our lattice structure 
predicts that just such an association of three TRIM5 RING domains will occur at local 
three-fold axes in the hexagonal net. Hence, formation of the hexagonal TRIM5 lattice may 
not only enhance binding avidity, but also activate the ubiquitin signaling cascade that 




4.4 Experimental procedures 
4.4.1 Plasmids, cells and antibodies  
HEK 293T and HeLa-M cells were grown in DMEM media (Gibco) supplemented with 
10% heat-inactivated FCS and 2 mM L-Glutamine, at 37°C with 5% CO2. Plasmid 
constructs for virus production and for expressing TRIM5, CA and OSF-CypA in 
mammalian, insect and bacterial cells were created by standard cloning and mutagenesis 
methods. 
 
4.4.2 Expression and purification of TRIM5 proteins 
Recombinant baculoviruses expressing TRIM5 proteins with either N-terminal One-
STrEP-FLAG (OSF) or C-terminal FLAG-One-STrEP (FOS) PreScission protease-
cleavable tags were generated using the Bac-to-Bac baculovirus expression system (Life 
Technologies). Suspension SF9 insect cells (2 L at 2 x 106 cells/ml) grown in ESF-921 
medium (Expression Systems) were infected with recombinant baculoviruses at 
multiplicities of infection of 10, and harvested by centrifugation 48 hours later. All 
purification steps were performed at 4°C. Cell pellets were resuspended in 5 times the pellet 
volume of lysis buffer (70 mM N-Cyclohexyl-2-aminoethanesulfonic acid (CHES), 100 
mM NDSB-256, 1.5% Triton X-100, 100 nM ZnCl2, 1 mM Tris(2-carboxyethyl)phosphine 
(TCEP), 0.7%  protease inhibitor cocktail (v/v, Sigma), 100 U avidin, pH 10) and lysed by 
freeze-thaw and sonication (3 x 30 seconds on ice; Branson sonifier 450, 50% duty cycle, 
50% output). Cell lysates were clarified by ultracentrifugation at 184,000xg (Beckman Ti 
50.2 rotor) for 1 hour. The supernatants were filtered (0.45 μm) and loaded onto a 5 ml 
StrepTrap HP column (GE Healthcare) pre-equilibrated in binding buffer (20 mM CHES, 
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100 nM ZnCl2, 1 mM TCEP, pH 10). The column was washed with 20 column volumes 
(CV) of binding buffer supplemented with 1 M NaCl and 100 U avidin (VWR), followed 
by 5 CV of binding buffer, and the protein was eluted in 6 CV binding buffer supplemented 
with 2.5 mM D-desthiobiotin (Sigma). The eluate was diluted to 0.3 mg/ml protein in 
binding buffer to minimize protein loss due to self-assembly, and dialyzed overnight 
against 1L cleavage buffer (25 mM Tris, 1 mM TCEP, pH 8) supplemented with ~ 1:100 
(by mass, enzyme:substrate) His6-HRV14-3C and His6-Usp2 enzymes to remove the OSF 
tag and any ubiquitin chains added during insect cell expression. TRIM5αhu and TRIMCyp 
formed soluble/insoluble aggregates at pH 8 and were therefore dialyzed against 20 mM 
CHES, 1 mM TCEP, pH 9. Most TRIM5 proteins were sensitive to nonspecific internal 
proteolysis by HRV14-3C protease. We therefore used the minimal amount (which differed 
between constructs) required to completely cleave the OSF tag overnight. When cleavage 
was complete, the pH of protein solution was adjusted to 10 by direct addition of 1M 
CHES, pH 10, to a final concentration of 100 mM. The sample was applied onto two 
tandem 5 ml HiTrap Q HP columns (GE Healthcare) pre-equilibrated with binding buffer, 
and eluted with a 12 CV linear NaCl gradient (0-1 M) in binding buffer. Fractions 
containing TRIM5 proteins were pooled, dialyzed against 1 L binding buffer for at least 4 
hours, loaded onto a HiLoad 16/600 Superdex 200 gel filtration column (GE Healthcare) 
pre-equilibrated with binding buffer and eluted in 1 CV of binding buffer. Fractions 
corresponding to TRIM5 dimers were pooled and concentrated to 1 mg/ml using Vivaspin 
20 concentrator (10,000 MWCO PES for TRIM5αAGMpyg ΔSPRY and 30,000 MWCO PES 
for full-length TRIM5α and TRIMCyp, Sartorius Stedim). Average yields were 4 mg (1.3-
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9.6 mg) per 1L insect cell culture. The protein identities were confirmed by electrospray 
ionization mass spectrometry.  
 
4.4.3 TRIM5 2D crystallization 
TRIM5-21R proteins were expressed, purified and crystallized as previously described 
(23), except that the TRIM5-21R1-300 assembly was modified from the original publication 
as follows. Spontaneous assembly was promoted by addition of an equal volume of 0.1M 
Sodium chloride, 0.1M Bicine pH-9.0, 20% PEG MME to the concentrated protein 
solution. 
Freshly purified TRIM5αAGMpyg protein was concentrated to 1-3 mg/ml and assembled 
by incubating at room temperature for 1 hour at 4°C for 1-2 days. For EM analyses, 5 μl 
sample aliquots were incubated on carbon-coated EM grids for 5 minutes. The grids were 
washed by placing each grid on a single 40 μL drop of 0.1M KCl for 3 minutes, briefly 
blotted and then stained on a single 20 μL drop of 2% uranyl acetate for an additional 3 
minutes. 
Unlike TRIM5αAGMpyg, TRIMCyp did not spontaneously assemble into hexagonal 
lattices following concentration. However, rare crystals could be observed when an equal 
volume of 0.01M Cobalt chloride hexahydrate, 0.1 M MES monohydrate pH 6.5 and 1.8 
M ammonium sulfate was added to freshly concentrated protein at ~1 mg/ml.   
 
4.4.4 Templated assembly of TRIM5 on hexagonal arrays of HIV-1 CA-NC 
As previously described (23), 2-dimensional crystals composed of crosslinked, 
hexagonal HIV-1 CA were prepared by incubating the HIV-1 CA-NCA14C/E45C/W184A (232 
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μM) protein with a small 25-TG oligo (143 μM). TRIM5 proteins were then added in 1- to 
10-fold molar excess, and the pH was immediately adjusted to 9 by direct addition of Tris 
buffer to a final concentration of 100 mM.  Samples were incubated for 1-96 hours, applied 
to carbon-coated EM grids for 60 seconds, and washed and stained as described above, and 
visualized by EM. 10-fold lower amounts were sufficient for TRIMCypK283D,Q287D 
templated assembly. 
 
4.4.5 Bacterial protein expression and purification  
4.4.5.1 OSF-Cyclophilin A (OSF-CypA) 
OSF-CypA was expressed in E. coli Rosetta (λDE3) pLysS cells (Stratagene) grown in 
ZYP-5052 media using an autoinduction system (81). Cells were lysed on ice by sonication 
in lysis buffer (50 mM Tris, pH 8, 50 mM NaCl, 10 mM β-mercaptoethanol (β-ME), 0.2% 
(w/v) deoxycholate, 2.5 nmol avidin, 20 μg/ml DNAse) supplemented with protease 
inhibitors (20 μg/ml PMSF, 0.4 μg/ml pepstatin, 0.8 μg/ml leupeptin and 1.6 μg/ml 
aprotinin). All purification steps were performed at 4°C. Cell lysates were clarified by 
centrifugation at 15,000 rpm (Beckman JA-20 rotor) for 45 minutes, filtered (0.45 μm) and 
loaded onto two 5 ml tandem StrepTrap HP columns (GE Healthcare) pre-equilibrated in 
binding buffer (100 mM Tris, 150 mM NaCl, 10 mM β-ME, pH 8). The column was 
washed with 10 CV of binding buffer and OSF-CypA was eluted in 3CV of the same buffer 
supplemented with 2.5mM D-desthiobiotin. The protein was dialyzed against Q buffer (50 
mM Tris, 50 mM NaCl, 10 mM β-ME, pH 8) and loaded onto two connected 5 ml HiTrap 
HP Q-Sepharose anion exchange columns (GE Healthcare) pre-equilbrated in the same 
buffer. The OSF-CypA-containing flowthrough was collected and concentrated using 
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Amicon Stirred Ultrafiltration Cells (Millipore). OSF-CypA (>99% pure) was obtained in 
high yields (～100 mg per 1L bacterial culture) and its identity was confirmed by ESI-MS 
(MWexp =23,806 Da, MWcalc, -Met1=23,807 Da).  
 
4.4.5.2 HIV-1 CAA14C/E45C/A92E 
The plasmid for expressing HIV-1 CA A14C/E45C/A92E was kindly provided by Dr. 
Owen Pornillos. E.coli Rosetta (λDE3) pLysS cells (Stratagene) were grown to an OD600 
nm of 0.6 in LB medium at 37°C, cooled to 19°C and protein expression was induced with 
1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and incubated overnight with shaking.  
HIV-1 CA proteins were purified and assembled into tubes as previously described (49), 
except that a higher concentration of DTT (100 mM) was used during protein purification 
to improve solubility and increase yields. Cells were lysed as described above and proteins 
were purified from clarified lysates by ammonium sulfate precipitation, dialyzed against 
25 mM KMOPS, 100 mM DTT, pH 6.5 and loaded onto a 5 ml HiTrap Q HP column (GE 
Healthcare) pre-equilibrated with the same buffer. The flowthrough was applied onto a 5 
ml Hi-Load SP Sepharose High Performance column (GE Lifesciences) and eluted with a 
linear NaCl gradient (0-500 mM) in the same buffer. Fractions containing CA proteins 
were pooled and dialyzed overnight against storage buffer (20 mM Tris, 40 mM NaCl and 
100 mM DTT, pH 8). The CA proteins were then concentrated to a stock of 3 mg/ml using 
Vivaspin 20 concentrator (10,000 MWCO PES, Sartorius Stedim) and stored at -80°C. 
Yields were ~20 mg per 1L of culture and the protein identity was confirmed by ESI-MS 




4.4.6 Assembly of hyperstable CA tubes 
CA tubes were assembled at 1 mg/ml by dialysis against dialysis buffer (20 mM Tris 
pH 8.0, 1M NaCl and 100 mM DTT) at 4°C overnight, followed by dialysis against the 
same buffer lacking DTT overnight to allow the formation of disulfide crosslinks within 
the CA hexamers. Disulfide-crosslinked CA tubes were then dialyzed against 20 mM Tris, 
40 mM NaCl, pH 8.0 and stored at 4°C.  
 
4.4.7 Preparation of HIV-1 virions  
HEK 293T cells (29 x 10 cm plates) were cotransfected (polyethylenimine, PEI, 
Polysciences) at 70-80% confluency with pLOX-GFP (5 μg DNA/plate) (82) and pCMV-
ΔR8.2 vectors (5 μg DNA/plate) (83) that expressed HIV structural proteins encoding the 
wild type or mutant CA sequences (A14C/E45C or A14C/E45C/A92E). 40 hours later, the 
virus-containing media was pooled, filtered (0.45 μm) and pelleted by ultracentrifugation 
through a 4 ml, 20% sucrose/PBS cushion in 25x89 mm polyallomer centrifuge tubes  
(Beckman Coulter) at 28,000 rpm (Beckman SW 32 Ti rotor) for 2 hours at 4°C. 
Subsequent core purification steps were performed at 4°C.  
 
4.4.8 Sucrose gradient purification of HIV-1 cores 
Wild type HIV-1 cores and hyperstable HIV-1 A14C/E45C cores were isolated from 
virions using an adaptation of a sucrose gradient spin-through method (44, 50). Virion 
pellets were resuspended with 2.4 ml ST buffer (20 mM Tris, 75 mM NaCl, pH 7.4). 6 x 
11.5 ml 30-70% (w/v) continuous sucrose gradients in ST buffer were made in 14x89 mm 
polyallomer centrifuge tubes (Beckman Coulter) using a gradient maker (Biocomp). The 
121 
 
gradients were overlaid with a 300 μl 15% (w/v) sucrose cushion in ST buffer containing 
0.5% Triton X-100 (to delipidate the virions as they migrated through the cushion) and 
then with a 300 μl nondetergent barrier layer (7.5% sucrose in ST buffer), which protected 
virions from premature detergent exposure. Concentrated virions were applied to the top 
of the gradient and centrifuged through the cushion and gradient at 35,000 rpm (Beckman 
SW41Ti rotor) for 16 hours. 12 x 1 ml fractions were collected from the bottom of each 
tube and the density of each fraction was determined from the refractive index using a 
digital refractometer (Leica). The CA content in each fraction was analyzed by western 
blotting using rabbit anti-HIV-1 CA polyclonal antibodies (made in-house, 1:3000 
dilution).  Fractions 10-12 (density = 1.22-1.27 g/ml), which contained intact HIV-1 cores, 
were pooled, diluted with ST buffer to 14 ml and subjected to ultracentrifugation at 35,000 
rpm (Beckman SW41Ti rotor) for 2 hours. The pelleted cores were resuspended in ST 
buffer. 
 
4.4.9 Affinity purification of HIV-1 cores 
2.4 ml of concentrated virions in PBS were mixed gently with an equal volume of lysis 
buffer (1% Triton X-100, 100 mM Tris, 2M NaCl, pH 8) in the presence of 35 μM OSF-
CypA and incubated for 3 minutes. 8 mg of MagStrep”type2HC” beads (IBA GmbH) were 
added to the lysed virions and mixed gently by inversion for 7 minutes to allow OSF-CypA 
to bind the membrane-stripped cores. The sample was then placed on a PolyATtract system 
1000 magnet separation stand (Promega) for 3 minutes, and the supernatant (‘Flow-
through’ Figure 4.7D) was removed. Captured cores were washed 10 times with high salt 
buffer (50 mM Tris, 1M NaCl, pH 8) to remove unbound CA proteins and contaminating 
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vesicles and the final wash sample was saved for western blot analysis (‘Wash’ in Figure 
4.7D). Cores were eluted in 150 μl of 50 mM Tris (pH 8), 75 mM NaCl supplemented with 
40 μM Cyclosporine A (Sigma-Aldrich) buffer and incubated with inversion for 40 
minutes. The sample was briefly centrifuged in a tabletop ultracentrifuge at 2000 rpm for 
5 seconds and placed on a Magnesphere Technology Magnetic Separation Stand (Promega) 
for 5 minutes. The supernatant containing the purified cores (‘Eluate’ in Figure 4.7D) was 
collected and used in the experiments shown in Figures 4.6, 4.7, 4.8, 4.9 and 4.10. Beads 
before and after CsA elution were also saved for western blot analyses (Figure 4.7). 
 
4.4.10 Characterization of purified hyperstable cores  
4.4.10.1 Core yields 
Virus inputs and core yields were quantified by western blot densitometry against a 
standard curve of recombinant CA proteins for reference. The recovery of cores from 
virions was calculated by normalizing core yields to corresponding virus inputs, which 
were set to 100%. As illustrated in Figure 4.6, disulfide crosslinks apparently stabilized 
HIV-1 cores, resulting in a ~four-fold increase in the core recovery (0.8±1%; core yields: 
0.6±0.5 μg CA; virus inputs: 100±80 μg CA, n=10) compared to wild type cores 
(0.2±0.1%; core yields: 0.08±0.05 μg CA; virus inputs: 40±30 μg CA, n=7). The affinity 
purification method consistently produced ~four-fold higher recoveries still of hyperstable 
HIV-1 A14C/E45C cores (3±2%; core yields: 1±0.6 μg CA; virus input: 40±8 μg CA, n=3) 
than the sucrose gradient spin-through method. Core recovery was not affected by the 




4.4.10.2 Analyses of HIV-1 core morphologies 
Particles were imaged by negative stain EM and scored as “tubular” if their edges 
appeared parallel, as “spherical” if they were spherical or elliptical or as “conical” if they 
lacked the above properties. The final class included conical, triangular, bullet-shaped and 
coffin-shaped cores. Particles were not scored if they were obscured by other cores.  
 
4.4.10.3 Disulfide crosslinks 
To examine the extents of disulfide crosslinks within purified cores, sucrose gradient 
fractions 7-9 and 10-12 were pooled separately, mixed with SDS-PAGE sample loading 
buffer lacking β-ME (or containing the concentrations designated in Figure 4.6C), heated 
at 95°C for 10 minutes, and electrophoresed on 4-15% gradient SDS polyacrylamide gels 
(Bio-Rad) and analyzed by western blotting. 
 
4.4.11 CA tube binding experiments 
CA tube binding experiments were performed as previously described, with minor 
modifications (5, 23, 44). Recombinant TRIM5α and TRIMCyp proteins (0.25 μM) were 
incubated alone or with CAA14C/E45C/A92E tubes (2 μM) in binding buffer (20 mM HEPES, 
25 mM NaCl, 1mM TCEP, pH 7.2) in a final volume of 225 μl at 4 °C for 1 hour. Aliquots 
(10 μl) of the incubation mixtures were mixed with 2X SDS-PAGE sample loading buffer 
for assessment of protein amounts in the inputs.  Aliquots (200 μl) of the mixtures were 
layered onto a 60% (w/v) sucrose/PBS cushion (4 ml, prepared in binding buffer lacking 
TCEP) and centrifuged at 34,000 rpm for 30 minutes in a Beckman SW50.1 rotor at 4°C 
to separate free TRIM5α or TRIMCyp and unassembled CA proteins from CA tube-bound 
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TRIM5 proteins and pelletable CA tubes. Following centrifugation, aliquots (45 μl) of 
supernatant (500 μl in total) were mixed with 4X SDS-PAGE sample loading buffer, and 
the pellets were resuspended in 25 μl 1X SDS-PAGE sample loading buffer. The TRIM5 
and CA proteins in the input (3%), supernatant (3%) and pellet (30%) were separated by 
12% SDS-PAGE and analyzed by western blotting as described above. 
 
4.4.12 Core binding experiments 
Recombinant TRIM5αAGMpyg (0.5 μM) and TRIM5αCPZ (0.5 μM) were incubated at 4 
°C for 1 hour alone or with hyperstable HIV-1 cores (0.5-1 μM) in binding buffer (40 mM 
HEPES, 50 mM NaCl, 1 mM TCEP, pH 7.2) in a final volume of 75 μl. Rhesus TRIM5αrh 
(0.25 μM) was incubated alone or with hyperstable cores under slightly more alkali 
conditions (40 mM Tris, 50 mM NaCl, 1 mM TCEP, pH 8) to minimize untemplated 
assembly of TRIM5α during sedimentation. Aliquots (5 μl) of the mixtures were mixed 
with 2X SDS-PAGE sample loading buffer (‘Input’ in Figure 4.8). The mixtures were 
layered onto a 30% (w/v) sucrose/PBS cushion (4 ml, prepared in binding buffer lacking 
TCEP) and centrifuged at 40,000 rpm for 2.5 hours in a Beckman SW50.1 rotor to separate 
free TRIM5α and unassembled CA proteins from capsid-bound TRIM5 proteins and 
pelletable cores. Following centrifugation, aliquots (45 μl) of supernatant (500 μl in total) 
were mixed with 4X SDS-PAGE sample loading buffer, and the pellets were resuspended 
in 25 μl 1X SDS-PAGE sample loading buffer. The TRIM5 and CA proteins in the input 
(2%), supernatant (2%) and pellet (30%) were separated by 12% SDS-PAGE, 
electrophoretically transferred onto nitrocellulose membranes (Bio-Rad) and analyzed by 
western blotting with mouse anti-TRIM5α monoclonal (clone 5D5-1-1, NIH AIDS 
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Research and Reference Reagent Program, 1:1000 dilution) and rabbit anti-HIV-1 CA 
polyclonal (made in-house, 1:3000 dilution) antibodies. Secondary IRDye800cw-
conjugated Donkey anti-mouse IgG (1:10,000, Rockland) or IRDye700DX-conjugated 
Donkey anti-rabbit IgG (1:10,000, Rockland) antibodies were visualized using an Odyssey 
infrared imaging system (LI-COR Bioscience). The integrated intensities of protein bands 
on the western blots were measured using the Odyssey software (LI-COR Bioscience). The 
molar ratios of TRIM5αAGMpyg to CA in the pellets were estimated from standard curves 
constructed from known amounts of TRIM5αAGMpyg and CA loaded on the same gel. 
 
4.4.13 TRIM5-21R ECT 
TRIM5-21R and TRIM5-21RΔSPRY 2D crystals were prepared as described previously 
(Ganser-Pornillos etal 2011). To prepare samples for ECT, 3 µl of polymerized lattice was 
mixed with 10 nm Au fiducials and applied to a 2/2 holey carbon-coated Cu EM grid 
(Quantifoil). The sample was then transferred with forceps to the environment chamber of 
a Vitrobot Mark III (FEI) maintained at 25 °C and 80% relative humidity. Excess liquid 
was manually blotted from the grids on one side before plunging into liquid ethane. Cryo-
preserved grids were then imaged in a 300-kV FEI G2 Polara equipped with a field 
emission gun and energy filter (slit width set at 20 eV), and fitted with a K2 Summit direct 
detector. Tilt-series were collected over a series of angles ranging from -60 to +60 degrees 
using a step size of 1; 22,500x magnification (effective pixel size of raw data is 5 Å), a 
total dose of 150 e/Å2 and a defocus of -6 m. UCSF Tomo (84) was used to collect the tilt 
series and 3D reconstructions were carried out using a weighted back-projection algorithm 
tracking 10 nm fiducials in IMOD (85). Pixel size in the final reconstruction was 20 Å. 
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Subtomogram averages of the TRIM5-21R and TRIM5-21RΔSPRY lattices were 
generated using PEET in IMOD (86). 153 and 75 vertices were selected in the TRIM5-21R 
and TRIM5-21RΔSPRY 2D lattices, respectively, and a volume of 60 nm x 60 nm x 20 nm 
(x,y,z) centered on the refined positions of the selected vertices was used to generate the 
averaged volume. To localize the SPRY domain in the full length TRIM-21R lattice, the 
density values of the averaged lattice volumes were rescaled to reflect a mean value of zero 
and standard deviation of 10. The volumes were then aligned in Chimera (87) and the 
TRIM5-21RΔSPRY density values were subtracted from the TRIM5-21R volume. The 
resulting density difference map was contoured and displayed at 3 sigma above the mean. 
To quantify the variability in the TRIM5-21R hexagonal lattice, the refined positions 
of each vertex were used to calculate: 1) the distance between neighboring vertices, and 2) 
the average angle of hexamer edges extending from the 3-fold vertices. These values were 
entered into the imodsetvalues program in IMOD and a pseudo-colored model was 
generated to reflect length (colored lines) and average angles (colored spheres).   
 
4.4.14 Negative stain transmission electron microscopy 
3.5 μl sample solutions of undecorated or TRIM5-decorated CA tubes were spread onto 
the carbon side of freshly glow-discharged Formvar carbon-coated 200-mesh copper grids 
(Electron Microscopy Science). The samples were incubated for 4 minutes, rinsed briefly 
by flotation on a drop of 100 mM KCl, blotted dry, stained for 2 minutes in filtered, 
saturated uranyl acetate (or 1 minute of phosphotungstic acid (PTA)), blotted dry and 
allowed to air-dry. Samples were viewed on a JEOL JEM-1400 Plus transmission electron 
microscope operated at 120 kV accelerating voltage, and images were acquired as Gatan 
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Digital Micrograph 3 (DM3) files with a Gatan Ultrascan CCD camera or on a Hitachi 
7100 TEM at 75 kV accelerating voltage with a Gatan ORIUS CCD camera, and converted 
into JPEG images using ImageJ software (NIH Bethesda, MD, USA).  
 
4.4.15 ECT of TRIM5α-decorated HIV-1 cores 
4.4.15.1 Cryo-grid preparation 
TRIM5α-decorated HIV-1 cores were made by incubating 0.25 μM TRIM5αAGMpyg 
with 1 μM CA equivalents of hyperstable HIV-1 cores in 20 mM HEPES (pH 7.2), 25 mM 
NaCl and 1 mM TCEP at 4°C for 1 hour, a condition that permits saturated binding in the 
cosedimentation assay (data not shown).  Cores or TRIM5α-core complexes were mixed 
with BSA-coated colloidal gold particles (10 nm, SPI Supplies), which served as fiducials 
required for aligning the tilt stacked images. For crosslinked complexes, samples were 
incubated with 1 mM Sulfo-EGS before freezing. Samples (3.5 µl) were placed on the 
carbon side of freshly glow-discharged Quantifoil R2/2, 300 mesh holey carbon grids (SPI 
Supplies) for 1 minute, thinned by automatic blotting using FEI Vitrobot (-1.5 mm offset, 
6-8 seconds, with filter papers from both sides at 80-85% relative humidity) and vitrified 
by plunge-freezing into liquid ethane. The cryo-grid was transferred to the microscope 
using a cryo-transfer holder. 
 
4.4.15.2 Electron cryo-tomography (ECT) 
Images were collected using a FEI Polara 300kV FEG transmission electron 
microscope equipped with an energy filter (slit width 20 eV; Gatan) and a 4k x 4k x 4k K2 
Summit using the direct electron counting mode (Gatan). Pixels on the detector represented 
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0.26 nm (41,000x) at the specimen level. The tilt series were recorded from -60° to +60° 
with an increment of 1° and 4 μm underfocus. The cumulative dose of a tilt-series was 80-
100 e-/Å2. UCSF Tomo (84) was used for automatic acquisition of the tilt series and 2D 
projection images. The tilt series were aligned and binned by 4 into 1k x 1k using the IMOD 
software package (85) and 3D  reconstructions were calculated using the simultaneous 
reconstruction technique (SIRT) using the TOMO3D software package (88), or weighted 
back projection using IMOD. Noise reduction was performed using the nonlinear 
anisotropic diffusion (NAD) method in IMOD (89), typically using a K value of 0.03 – 
0.04 with 10 iterations. 
 
4.4.15.3 Segmentation and isosurface generation 
Segmentation and isosurface rendering was performed in Amira (FEI). Firstly the outer 
boundary of the HIV-1 core was manually identified and a material mask was generated 
inside the boundary. A second region of interest surrounding the core that typically 
extended 9 nm from the exterior surface was generated (densities inside this region 
correspond to TRIM5α protein).  The area inside the second region was segmented and an 
isosurface generated for the densities inside. Those islands containing six voxels or less in 
3D were deleted. The exterior layer of capsid protein within the HIV-1 core of the first 
material was also segmented using a similar threshold value and an isosurface was 
generated.  Movie image sequences were generated in .jpg format in Amira (FEI) and 
converted into movies using QuickTime Player 7. Photoshop CS6 (Adobe) was then used 




4.4.16 Screening for TRIM5 decoration on CA tubes 
TRIM5-tube complexes were prepared by incubating TRIM5α or TRIMCypK283D, Q287D 
with hyperstable CA tubes in 50 mM Tris, 7.7 mM NaCl buffer at 4°C.  Decoration 
conditions were surveyed over a range of TRIM5 concentrations (0.6-22.5 μM) at a 
constant CA concentration (7.5 μM) (corresponding to molar ratios of TRIM5 to CA of 
1:6, 1:1 and 3:1), pH values (8.0 and 9.0) and incubation times (4-32 hours). Conditions 
that gave the best TRIM5 decoration on CA tubes and minimal TRIM5 self-assemblies 
were determined by negative stain TEM. The resulting complexes were imaged on a JEOL 
JEM-1400 Plus transmission electron microscope as described above. Image contrast was 
adjusted to enhance the decoration patterns of TRIM5 proteins on CA tubes using Adobe 
Photoshop CS5. The spacings of hexagonal TRIM5 rings were measured using ImageJ.  
 
4.4.17 Deep-etch electron microscopy 
Deep etch EM of TRIM5-bound helical CA arrays were performed as described in (90). 
 
4.4.18 TRIM5 restriction assays 
HEK 293T cells were used to generate lentiviral vectors for transduction of HeLa cells 
for expression of TRIM5 proteins with a C-terminal Flag One-Strep tag. pCMV-ΔR8.2 
(structural genes), pCMV-VSVG (envelope) and CSII-IDR2 (contains a packaging signal 
and genes for TRIM5 and DsRed) were cotransfected in 293T cells. After 3 days, virion-
containing media was removed from the cells, passed through a 0.45 μm filter (Nalgene 
SFCA syringe filters), layered on top of a 20% sucrose cushion in HS buffer (10 mM 
HEPES pH 7.2 and 140 mM NaCl) and spun in an Optima L-90K Ultracentrifuge using a 
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SW 32 Ti rotor at 28,000 rpms for 2 hours. Virion containing pellets were resuspended in 
HS buffer, aliquoted, and frozen at -80°C. Thawed aliquots were titrated on HeLa cells to 
determine viral titers by monitoring the number of DsRed positive cells using fluorescence-
activated cell sorting (FACS). 
HeLa cells (1 x 105 cells per well of 6-well plate) were transduced with lentiviral 
vectors expressing different TRIM5 proteins at an MOI of 1. Three days after transduction, 
cells were split and reseeded at 5 x 104 cells per well of a 24-well plate and infected with 
increasing amounts of HIV-GFP per well.  The remaining cells were used for western blot 
analysis to determine TRIM5 expression levels. Three days after infection with HIV-GFP, 
cells were trypsinized and GFP and DsRed positive cells were counted using FACS.  Only 




Yen-Li Li purified and characterized HIV-1 cores and CA tubes and performed all 
binding assays and negative stain EM imaging. Dr. Barbie Ganser-Pornillos performed the 
TRIM5-CA 2D electron crystallography. Dr. Stephen Carter and Dr. Cora Woodward 
performed the ECT analyses. Dr. Devin Christensen performed the TRIM5 restriction 
assay and Robyn Roth performed the deep-etch electron microscopy. These authors 
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Mammalian TRIM5α and TRIMCyp restriction factors are E3 ubiquitin ligases that 
block reverse transcription of susceptible retroviruses by binding and accelerating capsid 
dissociation (1, 2). TRIM5 restriction is an active area of research, yet the central 
question of how capsid binding by TRIM5 proteins leads to capsid dissociation and/or 
degradation is still poorly understood. In one model for restriction, capsid binding 
triggers TRIM5α E3 Ub ligase activity, which in turn leads to proteasome recruitment, 
capsid disassembly and inhibition of reverse transcription (3-8). A recent study showed, 
however, that TRIM5α can also regulate selective autophagy by binding 
p62/Sequestosome-1 and Beclin-1, which recruit autophagosomes to degrade capsids (9). 
It is not yet clear how to reconcile the proteasomal and autophagic models. Capsid-bound 
TRIM5α also helps establish a cellular antiviral state by recruiting the heterodimeric 
ubiquitin conjugating enzyme, Ubc13/Uev1B, to synthesize K63-linked poly-Ub chains 
that recruit TAK1/TAB2 kinase complexes and activate AP-1 and NF-κB signaling ((10) 




Retroviral capsids are curved hexagonal shells comprising a few hundred CA protein 
hexamers and exactly 12 CA pentamers (reviewed in (11)). Capsid recognition is a 
challenging task for host restriction systems because capsids from different retroviruses 
vary greatly in shape, hexameric spacing and distribution, and CA sequence. (12-14). 
Even individual capsids from a single retrovirus, such as HIV-1, can differ in 
interhexameric CA spacings (~90-110 Å) and can be conical, cylindrical or spherical (15-
18). 
TRIM5 proteins have evolved a remarkable “pattern recognition” mechanism to bind 
structurally diverse capsids with high affinity (Chapters 2 and 4, (10, 19)). As illustrated 
in Figure 5.1A, TRIM5α comprises RING, B-box 2 and coiled-coiled domains 
(collectively known as RBCC or tripartite motif domains), followed by a C-terminal 
capsid-binding B30.2 (PRYSPRY) domain (or a cyclophilin A domain, in the case of 
TRIMCyp). The RING/B-box 2 and the coiled-coil/PRYSPRY domains are separated by 
L1 and L2 linker regions, respectively. The PRYSPRY and CypA domains of individual 
TRIM5 alleles can bind directly to different retroviral capsids, albeit with weak intrinsic 
affinities (20, 21). This weak affinity is amplified by powerful avidity effects that arise 
from coiled-coil-mediated TRIM5α dimerization and B-box 2-mediated higher-order 
self-assembly into flexible hexagonal nets (Figure 5.1B; Chapters 2 and 4). Thus, TRIM5 
proteins can tolerate capsid structural variability because they cooperatively assemble 











Figure 5.1 Model for the TRIM5α dimer. (A) TRIM5α domain architecture. Positions of 
structures used for modeling are highlighted by dashed boxes. Structures of human 
TRIM5α RING-L1 (black; PDB ID: 2ECV), assembly-incompetent rhesus 
TRIMCypE120K, R121D B-box 2-coiled-coil-L2 (red; PDB ID: 4TN3), and rhesus TRIM5α 
SPRY (blue; PDB IDs: 4B3N, 3UV9 and 2LM3). (B) Two-dimensional projection 
density map of TRIM5αAGMpyg reproduced from Chapter 4, Figure 4.2C. The unit cell 
parameters are a = b = 343, γ = 120°. (C) (top) The core of a TRIM5α dimer comprises 
two B-box 2 domains (red) packed against a 17 nm, antiparallel dimeric coiled-coil 
(blue). The L2 linker (green, disordered regions marked by dashed lines) folds back 
towards the center of the coiled-coil to present two capsid binding SPRY domains 
(orange) on one face of the coiled coil. Two RING domains (yellow) are modeled as 
mobile elements connected to B-box 2 domains by flexible L1 linkers. (bottom) Top view 










Atomic structures of assembled TRIM5α are not yet available, but NMR and X-ray 
structures of individual TRIM5 domains and the recent crystal structure of the rhesus 
TRIMCyp B-box 2-coiled-coil-L2 dimer (highlighted schematically by dashed boxes in  
Figure 5.1A) overlap sufficiently to permit modeling of the TRIM5α tertiary structure 
(Figure 5.1C) (22-26). The coiled-coil forms a ~17 nm-long antiparallel dimer (blue), and 
two B-box 2 domains (red) are attached to its N-terminal ends in a fixed orientation. The 
two L2 linker elements (green) at the C-terminus of the coiled-coil fold back towards the 
central two-fold axis to display two PRYSPRY domains (orange) that can presumably 
contact a capsid surface simultaneously. Finally, the two RING domains (yellow) are 
modeled as mobile domains that are connected to the B-box 2 domains via flexible L1 
linkers, although it is alternatively possible that they are also held in a fixed orientation. 
We aimed to learn the molecular basis of TRIM5 hexagonal assembly and capsid 
recognition by determining crystal structures of assembled TRIM5 and TRIM5-CA 
complexes. To this end, we discovered how to solubilize and purify dimeric TRIM5 
alleles in quantities and concentrations sufficient for 3D crystallization trials (Chapter 4) 
and performed crystal trials on constructs from 10 different mammalian TRIM5α alleles. 
 
5.2 Results 
5.2.1 Primate TRIM5 dimers can be purified in quantities  
sufficient for 3D crystallography 
Protein homologs often differ in crystallizability and provide a naturally occurring 
source of sequence variation for crystal screening (27). We therefore selected TRIM5α 




owl monkey TRIMCyp) for expression, purification and crystal screening (Figure 5.2A). 
Three crystallization constructs were designed for each TRIM5α allele (Figure 5.2A): (a) 
full-length TRIM5α, (b) a ΔV1 mutant that lacked the functionally important, but 
disordered V1 loop in the SPRY domain (see Figure 1.5 and refs. (25, 26)), and (c) a 
ΔSPRY variant that lacked the entire SPRY domain, but could nevertheless assemble into 
hexagonal lattices (Chapter 2; (19)). OneSTrEP-FLAG-tagged (OSF-tagged) TRIM5 
proteins were expressed using insect cell/baculovirus expression systems and purified by 
sequential Strep-Tactin affinity, Q anion exchange and Superdex-200 size exclusion 
chromatography (Figure 5.2B). Figure 5.2C shows the stepwise purification of a 
representative construct, chimpanzee TRIM5α ΔSPRY (residues 1-296). Figure 5.2D 
shows SDS-PAGE gels of Strep-Tactin affinity-purified full-length (left), ΔV1 (middle) 
and ΔSPRY (right) proteins for all TRIM5α alleles. The resulting dimers were stable in 
solution at pH 10 in the absence of added salt and could typically be concentrated to ~10 
mg/ml for crystal trials. Thus, TRIM5 solubility and self-assembly could be controlled 
using pH and ionic strength, with higher pH and low ionic strength favoring solubility 
(and conversely). 
 
5.2.2 Crystallization of African green monkey and chimpanzee  
TRIM5α ΔSPRY constructs 
Crystal trials were performed in collaboration with Prof. Chris Hill’s laboratory using 
a Phoenix crystallization robot (Art Robbins Scientific). We succeeded in crystallizing 
two constructs: African green monkey pygerythrus (AGMpyg) TRIM5α ΔSPRY 









Figure 5.2 Summary of strategies used for TRIM5 purification and 3D crystallization. (A) 
Full-length, ΔV1 constructs lacking the flexible V1 hypervariable loop in the SPRY 
domain and ΔSPRY constructs lacking the entire SPRY domain were designed for all of 
the listed TRIM5 alleles. (B) Insect cell lysates expressing TRIM5 proteins were purified 
using the following stepwise protocol: (a) Strep-Tactin affinity chromatography, (b) 
removal of the OSF tag and any attached Ub chains by Prescission protease and Usp2 
deubiquitylase treatment, (c) Q anion exchange chromatography and (d) Superdex 200 
gel filtration chromatography. (C) Coomassie-stained SDS-PAGE showing the step-wise 
purification of a representative construct, CPZ TRIM5α ΔSPRY (1-296). (D) Coomassie-
stained SDS-PAGE analysis of eluates from Strep-Tactin affinity chromatography of full-
length (left), ΔV1 (middle) and ΔSPRY constructs, showing partially-purified TRIM5 
proteins. Note that all TRIM5α ΔSPRY proteins contain intact N-terminal OSF tags, 
except for African green monkey tantalus TRIM5α ΔSPRY (AGMtan) and squirrel 
monkey (sq. m.) TRIM5α ΔSPRY, which were eluted by PreScission protease cleavage. 














constructs crystallized in 100 mM HEPES pH 7.5, 500 mM Magnesium Formate at 20 
°C. The AGMpyg TRIM5α ΔSPRY crystals had a hexagonal tabular crystal habit (Figure 
5.3A, top), diffracted (anisotropically) only to ~12 Å resolution, and were highly 
sensitive to radiation damage. In spite of the limited diffraction order, we were able to 
collect datasets with >80% completeness and ~14 Å resolution at beamline 12-2 of the 
Stanford Synchrotron Radiation Lightsource (SSRL). The crystals were indexed to the 
space group P622 with unit cell dimensions of 686 Å x 686 Å x 135 Å. Our attempts to 
determine phases by experimental and molecular replacement approaches failed, but the 
unit cell dimensions and symmetry indicated that the crystals likely comprised stacks of 
dimeric TRIM5α hexagonal assemblies. The unit cell a and b dimensions (686 Å) were 
exactly twice those observed in 2D projection maps of full-length AGMpyg TRIM5α 2D 
crystals (343 Å; see Figure 4.2C). This observation suggests the presence of translational 
pseudosymmetry, which is the presence of two or more copies of TRIM5α in the unit cell 
that are related to each other by a simple translation. It must be stressed, however, that 
translational pseudosymmetry can often result in misindexing of the data and/or obsure 
the presence of any twinning (28).  
The CPZ TRIM5α ΔSPRY crystals (Figure 5.3A, bottom) had trigonal pyramidal or 
triangular prismatic habits and diffracted to 5.1 Å resolution. ~90% complete, 6.8 Å-
resolution datasets were collected at SSRL beamline 12-2 and indexed in space group 
R32:H, with cell dimensions of 303 Å x 303 Å x 59 Å. Unfortunately, anomalous 
diffraction from the TRIM5α Zn atoms did not provide sufficient phasing power and the 
crystals were extremely sensitive to heavy metal soaks. Molecular replacement using the 







Figure 5.3 TRIM5α 3D crystallization. Crystals, unit cell parameters and representative 
X-ray diffraction patterns obtained from crystallization trials of (A) TRIM5αAGMpyg 
ΔSPRY (1-298) and (B) TRIM5αCPZ ΔSPRY (1-296). (B) (left) Coomassie-stained SDS-
PAGE of TRIM5αAGMpyg ΔSPRY (1-298) (Input) proteolyzed by Zymit in solution 
(+Zymit) and in crystals (Crystals). “REVKL” were the five N-terminal residues of the 
major band identified by N-terminal sequencing. (right) Compiled ESI mass spectrum of 
TRIM5αAGMpyg ΔSPRY (1-298) (calculated intact mass: 35131 Da) demonstrates that the 
major species (experimental mass: 25926.3 Da) is TRIM5αAGMpyg (82-298) (calculated 
mass: 25929 Da). (C) Schematic showing the site of proteolysis in the L1 linker. The 
“second generation” ΔRING, ΔRING/ΔSPRY and ΔRING/ ΔV1 constructs are also 
illustrated. (D) Image showing that the purified ΔRING/ΔSPRY construct, GP-
TRIM5αAGMpyg (82-298), can crystallize into similar hexagonal tabular crystals from both 
robotic- and hand-poured vapor diffusion trials. (E) NMR structure of the human 
TRIM5α B-box 2 domain (PDB ID: 2YRG), with structured residues in red, unstructured 
residues in green and the conserved Arg121 sidechain in purple. (F) Image showing that 
GP-TRIM5αAGMpyg (94-298), a ΔRING/ΔSPRY that lacks the unstructured residues 















as well as the inherent difficulty of performing molecular replacement at low resolution 
on elongated molecules such as coiled-coils (and α-helices in general). 
 
5.2.3 Proteolytic removal of the RING domain in situ promoted  
crystal growth 
The symmetry and cell dimensions of the CPZ TRIM5α ΔSPRY crystals were 
inconsistent with the hexagonal symmetry and dimensions expected from 2D 
crystallographic studies of TRIM5α (Chapters 2 and 4). Furthermore, crystals of both 
constructs were recalcitrant to all optimization attempts, such as pH, precipitant and 
temperature variation, micro- and macro-seeding, random matrix microseeding (rMMS) 
and additive screening. Indeed, the crystals only grew in 96-well robot trays despite 
repeated attempts to reproduce them by hand pipetting. The explanation for these unusual 
observations was clear when we analyzed the crystals by SDS-PAGE. This analysis 
revealed that both the AGMpyg and CPZ TRIM5α ΔSPRY proteins had been proteolyzed 
in situ by Zymit®, a proprietary mixture of a protease, amylase and detergent that was 
used to clean the sample dispensing needle of the Phoenix crystallization robot (Figure 
5.3B, compare lanes marked ‘Input’ and ‘Crystals’). The site of proteolysis was identified 
using N-terminal protein sequencing and electrospray ionization-mass spectrometry (ESI-
MS) (Figure 5.3B). These analyses revealed that both constructs were cleaved at 
equivalent sites in the L1 linker: Leu81/Arg82 (AGMpyg) and Leu80/Arg81 (CPZ). This 
local region appears to be particularly sensitive to proteolysis because an earlier study 
had also reported proteolysis at the C-terminus of this Arg residue when the chimeric 




that residues in the L1 linker may be unstructured or accessible in solution. In any event, 
we conclude that serendipitous proteolysis during crystal trials led to RING-L1 removal 
and facilitated crystallization of the B-box 2-coiled-coil-L2 fragments, AGMpyg 
TRIM5α (82-298) and CPZ TRIM5α (81-296). 
 
5.2.4 Insect cell-expressed ΔRING constructs form similar crystals 
To test whether constructs that comprised only the B-box 2-coiled-coil-L2 region 
(i.e., ΔRING, ΔSPRY) could yield improved crystals, I cloned, expressed and purified N-
terminal OSF-tagged AGMpyg TRIM5α (82-298) and CPZ TRIM5α (81-296) (Figure 
5.3C and data not shown). Unlike the fragments generated by Zymit-proteolysis, these 
constructs contained an N-terminal Gly-Pro dipeptide that remained after the N-terminal 
OSF tag was removed by PreScission protease treatment. As shown in Figure 5.3D, Gly-
Pro-AGMpyg TRIM5α (82-298) also crystallized into hexagonal tabular crystals, both in 
robotic and hand trays. However, the X-ray diffraction properties of these crystals remain 
to be studied. 
A recent NMR structure of the human TRIM5α B-box 2 domain (PDB ID: 2YRG) 
reveals additional information on the protein’s domain architecture. In this structure, the 
region from Arg82 (the first residue in the ΔRING fragments) to Leu93 of the L1 linker 
is unstructured (i.e., Val94 is the first ordered residue) (Figure 5.3E, disordered residues 
are depicted in green, and ordered residues in red) (23). We therefore purified a new 
construct, Gly-Pro-AGMpyg TRIM5α (94-298), that lacked the unstructured residues. 
Interestingly, this construct crystallized in a new crystal habit (Figure 5.3F; thin needle-




perhaps improved its assembly properties. We now plan to optimize these crystals further 
and conduct X-ray diffraction studies. We are also concerned that the non-native Gly-Pro 
overhang at the N-terminus of the ΔRING constructs may disrupt crystal growth by 
interfering with B-box 2 assembly interactions at the three-fold interface of the TRIM5 
hexagonal lattice. We have therefore designed constructs that express N-terminal OSF-
SUMOstar tags that can be completely removed by SUMOstar protease (LifeSensors, 
Malvern, PA) without any overhanging residues (30). We have also designed longer 
constructs that include the SPRY domain but lack the RING domain (Figure 5.3C). These 
constructs will be used in future 3D crystallization trials with hexameric CA assemblies. 
Taken together, our results suggest that the RING domain may not be absolutely required 
for hexagonal lattice formation and that trimeric B-box 2 and dimeric coiled-coil 
interactions may suffice to support TRIM5α hexagonal lattice formation (Figure 5.4). 
 
5.3 Discussion and future directions 
TRIM5 proteins spontaneously self-assemble under physiological conditions in vitro, 
making them difficult to purify and concentrate for crystallization studies (19). In this 
study, we overcame these technical hurdles and have crystallized the B-box 2-coiled-coil-
L2 linker of African green monkey and chimpanzee TRIM5α. Although we have thus far 
failed to determine the structure of an assembled TRIM5α construct, we recently 
discovered that standard techniques to optimize our crystals in hand trays failed owing to 
serendipitous proteolysis of the RING domain during robotic crystal trials of RING-
containing constructs. This observation prompted us to go back and redesign new 













Figure 5.4 A model for the TRIM5α hexagonal lattice (A) surface representation with a 
close-up of the putative B-box 2 domain-mediated three-fold interface, inset. Domains 
are colored following the scheme in Figure 5.1A. (B) RING domain dimerization. The N-
terminal residues (black) and the C-terminal L1 linker (green) form a four-helix bundle 
that stabilizes RING domain core interactions (D. Ivanov, personal communication). The 
analogous dimer formed by the RING domain of TRIM37 (PDB ID: 3LRQ) has been 
used in the figure because coordinates for the structure of the TRIM5α RING dimer are 


















presumably equivalent lattices, but the X-ray diffraction properties of these new crystals 
are yet to be studied. The hexagonal symmetry and a=b=686 Å unit cell dimensions of 
the AGMpyg TRIM5α (82-298) crystals are consistent with independent electron 
crystallographic analyses of full-length AGMpyg TRIM5α (Chapter 4) and indicate that 
our 3D crystals may comprise stacked sheets of TRIM5α hexagonal lattices. Hexagonal 
assembly therefore apparently does not absolutely require the N-terminal RING-L1 and 
C-terminal SPRY regions and the B-box 2-coiled-coil-L2 region therefore appears to 
constitute the TRIM5 “self-assembly core”, as others have previously suggested (24, 31). 
If this is correct, then the B-box 2 domain must trimerize at the three-fold interface of the 
hexagonal lattice (Figure 5.1B). B-box 2 trimerization and coiled-coil dimerization (24, 
32) alone could, in principle, then combine to generate TRIM5 hexagonal rings, provided 
the two symmetry axes are parallel.  
Based on this idea, we have produced a tentative model for the TRIM5 hexagonal 
lattice (Figure 5.4A), by (a) positioning a monomer of rhesus TRIMCyp B-box 2-coiled-
coil-L2 (24), so that the noncrystallographic two-fold symmetry axis of the coiled-coil 
coincides exactly with the crystallographic two-fold axis of a theoretical P6 lattice with 
a=b=343 Å (experimentally determined by 2D electron crystallography; Chapter 4, see 
Figure 4.2) and c=100 Å (chosen to be large enough to prevent atomic clashes between 
successive layers); and (b) rotating the molecule about the two-fold axis by an arbitrary 
angle (14° clockwise) until application of the P6 space group symmetry operations results 
in a continuous hexagonal lattice. This model predicts that the functionally important 
Arg121 residue of the B-box 2 domain (33, 34) could stabilize the three-fold interface by 




sidechain atoms of both residues are shown as spheres). Mutating either residue to one of 
opposite charge should therefore diminish TRIM5α restriction activity and the 
R121E/E135R double mutation should rescue restriction. Consistent with this model, 
TRIM5αR121E indeed lacks self-assembly, capsid binding and restriction abilities (19, 33). 
Dr. Devin Christensen, a postdoc in our laboratory, is currently testing the activities of 
the single E135R and double R121E/E135R mutants in a restriction assay. 
Recent unpublished studies from the Ivanov laboratory have demonstrated that the 
TRIM5α RING domain must dimerize to function (D. Ivanov, personal communication). 
The Zn-bound cores of individual RING monomers interact to form the dimer interface, 
which is further stabilized by a four-helix bundle formed by flexible loops that flank the 
RING domain (Figure 5.4B). RING dimerization will result in a symmetry mismatch 
between the dimeric RING domains and (putative) trimeric B-box 2 domains, which is 
depicted in Figure 5.4 using the dimeric structure of the TRIM37 RING (PDB ID: 
3LRQ). Two of the local RING domains may therefore dimerize to leave an unpaired 
third RING domain (not shown for clarity). An intriguing alternative explanation is that 
the 2D projection structures of assembled TRIM5α (Figure 5.1B) are actually composed 
of two hexagonal layers stacked face-to-face and that the 6 resulting RING domains, 3 
from each layer, form a trimer of dimers between the two layers, as observed in the 
crystal structure of the RING domain from cIAP2 (PDB ID: 3EB6) (35). 2D projection 
maps obtained by electron crystallography cannot typically distinguish multilayered from 
monolayered 2D crystals. This explanation would eliminate the symmetry mismatch 
between the RING and B-box 2 domains, but lacks any supporting experimental 




the RING domains when TRIM5 assembles on capsids apparently underlies activation of 
RING E3 ubiquitin ligase activity to initiate antiviral signaling and trigger accelerated 
capsid dissociation (6, 10). 
In summary, we are continuing our TRIM5 crystallographic studies because we 
anticipate that these studies, if successful, will help reveal the structural basis of TRIM5 
assembly and thereby provide mechanistic insights into retroviral restriction. Our 
ultimate goal is to understand the molecular basis of capsid recognition by determining 
structures of TRIM5 proteins in complex with mimics of the capsid surface. Toward this 
end, we plan to conduct co-crystallization trials with stable hexameric assemblies of 
HIV-1 CA (36, 37). 
 
5.4 Materials and methods 
5.4.1 Construction, expression and purification of recombinant TRIM5 
pLPCX vectors encoding TRIM5 cDNA from all species used in this study were kind 
gifts from Dr. Joseph Sodroski (Dana Farber Cancer Institute, Boston, MA). N-terminal 
OneSTrEP-FLAG-tagged, full-length, ΔV1 and ΔSPRY TRIM5 cDNAs were subcloned 
into pFastBac1 baculovirus entry vectors using standard sequence and ligation 
independent cloning (SLIC) methods (38). Recombinant Bac-to-bac baculoviruses 
expressing these proteins were generated using manufacturer-recommended procedures 
(Life technologies) in a high-throughput format developed by the Joint Center for 
Innovative Membrane Protein Technologies (JCIMPT) (39). All proteins were expressed 





5.4 2 Crystallization 
Sitting drop, vapor diffusion trials were performed in 96-well Intelliplates (Art 
Robbins Scientific) using a Phoenix crystallization robot (Art Robbins Scientific) and 
incubated at 4, 13, 20 or 28 °C in constant temperature rooms. Crystals of AGMpyg and 
CPZ TRIM5α ΔSPRY were obtained by serendipitous in situ proteolysis (see Section 4-
2, Results). The crystals grew at 20 °C after 3 days (AGMpyg) or 2 weeks (CPZ) in 100 
mM HEPES pH 7.0-8.0, 300-800 mM Magnesium Formate, 1 µM Zinc Chloride. 
Crystals were cryoprotected in 20% ethylene glycol or in a mixture of 10% PEG200 and 
15% ethylene glycol. Data were collected remotely at SSRL beamline 12-2. Data 
reduction was carried out using HKL2000 or XDS (using the autoxds script available at 
SSRL). Crystallographic statistics for the best datasets from both constructs are given in 
Table 5.1. 
Electrospray ionization mass spectrometry was performed by Dr. Chad Nelson and 
Dr. Krishna Parsawar at the University of Utah mass spectrometry core facility. N-
terminal sequencing was performed by Dr. John Schulze at the University of California at 
Davis proteomics core facility. 
 
Table 5.1 Data processing statistics 
Construct AGMpyg TRIM5α82-298 CPZ TRIM5α81-296 
Space group P622 R32:H 
Cell dimensions a = b = 686 Å, c = 158 Å 
 =  = 90o,  = 120o 
a = b = 298.3 Å, c = 58.8 Å 
 =  = 90o,  = 120o 
Resolution range, Å 80-14 38.8-6.48 
Wavelength, Å 1.2825 0.9795 
Rsym, % 11.8 10.4 
Mean <I>/σ<I> 25.06 3.6 
Completeness, % 83.7 90.6 
Average redundancy 10.6 4.1 
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